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ABSTRACT 
 
 
Tendinitis is a common cause of breakdown injury in equine athletes and accounts for 30% to 
50% of all racing injuries. The last decade has seen significant development in mesenchymal 
stem cell (MSC)-based therapies in tendon repair. The focus on tendon-derived progenitor cells 
(TDPCs) for tendon healing is based on the rationale that stem cells obtained from tendons are 
more phenotypically-committed or ‘primed’ for tenogenesis than cells from other tissues. The 
overall objective of this body of research is to characterize and evaluate equine tendon-derived 
progenitor cells for tendon healing in horses.  
 
TDPCs were isolated via a differential adhesion preplating screen that has been successfully used 
to isolate skeletal muscle-derived stem cells. Cell suspensions obtained via collagenase digestion 
of equine lateral digital extensor tendon (n=4) were serially transferred into adherent plates every 
12 hrs for 4 days. TDPCs obtained from the initial, third and seventh preplates were used for 
subsequent analyses. Growth/proliferation and basal tenogenic gene expression of the three 
TDPC fractions were largely similar. Preplating and subsequent monolayer expansion did not 
alter the immunophenotype (CD29+, CD44+, CD90+, and CD45−) and trilineage differentiation 
capacity of TDPC fractions. Overall, TDPCs were robustly osteogenic but exhibited 
comparatively weak adipogenic and chondrogenic capacities. These outcomes indicate that 
preplating does not enrich for tendon-derived progenitors during in vitro culture, and ‘whole 
tendon digest’-derived cells are as appropriate for cell-based therapies. 
 
In vitro growth characteristics of matched equine TDPCs and bone marrow MSCs (BM-MSCs) 
during monolayer expansion were assessed (n=6). Subsequently, third passage TDPCs and BM-
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MSCs were cultured on acellular tendon matrices for 7 days with or without insulin-like growth 
factor supplementation.  Matrix production and matrix gene expression were analyzed at the end 
of in vitro culture. During monolayer expansion, at each passage, the yield of TDPCs was 3-fold 
higher than the matched BM-MSCs. The viability of TDPCs on acellular tendon matrices was 
1.6-2.8 fold higher than BM-MSCs. New collagen and glycosaminoglycan syntheses were 
significantly greater in TDPC groups and in IGF-I–supplemented groups. The mRNA 
concentrations of collagen type I and III, and cartilage oligomeric matrix protein (COMP) were 
not significantly different between TDPC and BM-MSC groups. These in vitro results 
demonstrated that TDPCs may offer a useful resource for cell-based therapies for tendon healing.  
 
Lastly, the efficacy of TDPCs in an in-vivo equine flexor tendinitis model was evaluated. 
Collagenase-induced tendinitis was created in both front superficial digital flexor (SDF) tendons 
(n=8). Four weeks later, the forelimb tendon lesions were treated with 1 x 107 autogenous TDPCs 
or saline. Twelve weeks after forelimb TDPC injections, tendons were harvested for assessment 
of matrix gene expression, biochemical, biomechanical and histological characteristics. Collagen 
I and III, COMP and tenomodulin mRNA levels were similar in both TDPC and saline groups 
and higher than normal tendon. Yield and maximal stresses of the TDPC group were 
significantly greater than the saline group’s and similar to normal tendon. However, the elastic 
modulus of the TDPC and saline groups were not significantly different. Histological assessment 
of the repair tissues with Fourier transform-Second Harmonic generation imaging demonstrated 
that collagen alignment was significantly better in TDPC group than in the saline controls. In 
summary, TDPC administration improved the histological and biomechanical properties of 
collagenase-induced tendinitis lesions.  
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CHAPTER 1: INTRODUCTION 
 
 
Tendon injuries range from acute tendon rupture to chronic tendinopathy, and are among the 
most common orthopedic problems. Achilles tendon injuries, rotator cuff degenerative 
tendinopathy, flexor tendon injuries are common causes of disability and pain among people and 
sport/performance horses, respectively. Further, long-term disability is a frequent consequence, 
due to prolonged healing time and high rate of recurrence following the initial injury. Tendons 
are highly specialized connective tissues that transmit tensile forces between muscles and bones. 
Tendons are relatively hypocellular and hypovascular tissues, with little or no intrinsic 
regenerative capacity. Current therapies involve conservative management and/or surgical 
debridement and repair, depending on the location and severity of the pathology. Irrespective of 
the approach used, the resultant repair tissue is biomechanically inferior to healthy tendon and 
re-injury is common despite prolonged rehabilitation. 
 
Cell-based approaches to tendon healing have been widely investigated in experimental models 
of tendinitis with the goal of improving the quality of repair tissue. Mesenchymal stem cells 
(MSCs) derived from different sources, including tendon tissue, have been evaluated in both in 
vitro and in vivo models of tendon repair with promising results. The focus on tendon-derived 
progenitor cells (TDPCs) for tendon regeneration is based on the rationale that cells derived from 
the tendons will be phenotypically and biosynthetically more capable of stimulating functional 
repair than MSCs derived from other tissue sources. 
 
The objective of this body of research is to characterize equine TDPCs in vitro and subsequently 
assess their healing properties in an in vivo equine collagenase model of tendinitis. This thesis is 
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composed of a literature review and three original research chapters. The literature review 
(chapter 2) focuses on the biology of tendon-derived stem/progenitor cells (TDPC), their in vitro 
and in vivo characteristics, and their efficacy in improving healing in experimental models. This 
review was accepted for publication by the Journal of Stem Cell Research and Medicine [1]. 
 
The first experimental study (chapter 3) addressed the MSC characteristics of equine TDPCs 
isolated from the lateral digital extensor tendon via differential adherence preplating screen. In 
this chapter, in-vitro proliferation during monolayer expansion and immunophenotype of equine 
TDPCs were determined prior to trilineage differentiation. We then assessed the in vitro 
osteogenic, adipogenic and chondrogenic potential of equine TDPCs. The manuscript from this 
study has been accepted for publication by the journal Tissue Engineering: Part C Methods [2]. 
 
The second study (chapter 4) compared the in vitro growth characteristics of matched equine 
TDPCs and bone marrow MSCs (BM-MSCs) during monolayer expansion. Subsequently, equine 
TDPCs and BM-MSCs were cultured on acellular tendon matrices and matrix production and 
matrix gene expression were analyzed. This study was published in the American Journal of 
Veterinary Research [3]. 
 
The third study (chapter 5) evaluated the efficacy of autogenous TDPC injections in an in vivo 
collagenase model of equine superficial digital flexor tendinitis. The healing potential of TDPCs 
was assessed using transcriptional, biochemical, histological and biomechanical outcomes. The 
manuscript that describes this study was recently accepted for publication by the Journal of 
Orthopaedic Research [4].  
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CHAPTER 2: LITERATURE REVIEW 
 
 
This chapter was recently accepted for publication as a review article by the Journal of Stem Cell 
Research and Medicine.a  
 
Tendon injuries range from acute tendon rupture to chronic tendinopathy, and are among the 
most common orthopedic problems. Achilles tendon injuries account for up to 50% of all sports-
related injuries [1,2], while rotator cuff degenerative tendinopathy is a common cause of shoulder 
pain/disability [3]. Flexor tendon injuries are linked to several occupations in people [4] and in 
sport/performance horses [5]. Further, long-term disability is a frequent consequence, due to 
prolonged healing time and high rate of recurrence following the initial injury [6,7]. 
Consequently, the financial impact of tendon injuries is considerable.  
         
Tendons are highly specialized connective tissues that transmit tensile forces between muscles 
and bones. Tendons are relatively hypocellular and hypovascular tissues, with little or no 
intrinsic regenerative capacity. Current therapies involve conservative management and/or 
surgical debridement and repair, depending on the location and severity of the pathology [8,9]. 
Irrespective of the approach used, the resultant repair tissue is biomechanically inferior to 
healthy tendon and re-injury is common despite prolonged rehabilitation. Consequently, cell-
based approaches to tendon healing have been widely investigated in experimental models of 
tendinitis with the goal of improving the quality of repair tissue. Mesenchymal stem cells  
 
a Durgam, S.S., Stewart, M.C. 2016. Tendon-derived progenitor cells: In vitro characterization and clinical 
applications for tendon repair. Journal of Stem Cell Research and Medicine, 1, pp. 8-17.  
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(MSCs) derived from different sources have been evaluated in both in vitro and in vivo models 
of tendon repair and the outcomes have been recently reviewed [10-15].  
 
This review will specifically focus on tendon-derived stem/progenitor cells, their in vitro and in 
vivo characteristics, and their efficacy in improving tendon healing in experimental models. 
Several different terms have been used in the literature to describe the stem/progenitor cell 
populations within tendons. In this review, the term ‘tendon-derived progenitor cells’ (TDPCs) is 
used to refer to these cells.  
 
Tendon Structure and Function:  
Tendons are dense collagenous tissues that connect muscles to bones and are composed of a 
hierarchical arrangement of predominantly collagenous subunits (Figure 2.1). Morphologically, 
tendons contain a variable number of fascicles, which are comprised of multiple collagen fiber 
bundles. The fiber bundles contain many collagen fibrils [16,17]. These collagen units are 
oriented in the direction of the predominant tensile load. Tendon fascicles are bound together by 
a loose areolar connective tissue, the endotenon, which becomes confluent with the outer 
epitenon. The epitenon is surrounded by the peritenon; a fine connective tissue sheath which 
functions as an elastic sheath to permit free movement of the tendon against the surrounding 
structures. The collagen molecules are stabilized by intermolecular chemical crosslinks resulting 
in high tensile strength [18]. 
 
Histologically, tendons have a highly organized and anisotropic structure (Figure 2.2). Collagen 
fibers are aligned along the longitudinal axis in each fascicle. Tenocytes are located both within 
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and between the fascicles, arranged in rows along the direction of the collagen fibers [19]. A 
characteristic crimp pattern of collagen fibers is a typical ultra-structural feature of tendons 
(Figure 2.3). The crimps function as a buffer to provide immediate longitudinal elongation in 
response to physiological tensile loads [17]. 
         
Tendons can be classified as positional or energy-storing tendons. All tendons transmit forces 
from muscle to bone; however, energy-storing tendons have the additional function of extension 
and recoil to increase the efficiency of locomotion [19]. Tendons respond to tensile loads at 
multiple structural levels [20,21]. Crimp elongation provides a relatively modest (approximately 
3%) strain response to load. Elastic ‘sliding’ between adjacent fibers, fibrils and fascicles, rather, 
than direct ‘unit’ extension, provides the majority of tensile strain. In addition, recent evidence 
suggests the presence of helical substructures within the tendon fascicles, which provides a 
mechanism for efficient extension under load and recoil when unloaded [22]. Therefore, the 
collective mechanical properties of both the interfascicular and intrafascicular matrices are 
responsible for the functional capacity of tendons.  
 
Endogenous Tendon Healing: 
Healing tendons undergo the traditional phases of an initial inflammatory response, a 
proliferative phase and a remodeling phase [5]. The reactive inflammatory phase lasts for about a 
week, in the absence of ongoing injury, and is characterized by a marked increase in cross-
sectional area at and around the site of injury, consequent to local hemorrhage and edematous 
swelling. This is followed by inflammatory cell infiltration, primarily neutrophils and 
macrophages. The proliferative phase overlaps with the latter half of the inflammatory phase and 
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peaks in about 2-3 weeks. Neovascularization, local synthesis of chemokines, trophic factors and 
proliferation of fibroblasts are dominant features of this phase. These processes culminate in 
tenocyte proliferation and collagen synthesis leading to formation of immature fibrovascular 
tissue. The remodeling phase is characterized by formation of fibrous tissue. During this stage, 
the healing tissue undergoes changes in size and shape. This phase is divided into consolidation 
and maturation processes [23]. The repair tissue transitions from predominantly cellular to 
fibrous in nature, as new matrix is synthesized at the injury site. However, increased vascularity, 
neuronal infiltration and cellularity persist for up to 3 months post-injury [6,24,25] and the 
collagen architecture remains disorganized for several months (Figure 2.3). This results in 
reduced extensibility and elasticity of the repair tissue and predisposes the site to re-injury.  
 
Tendon-Derived Progenitor Cells:  
The focus on TDPCs for tendon regeneration is based on the rationale that cells derived from the 
target tissue (in this case, tendon) will be phenotypically and biosynthetically more capable of 
stimulating functional repair than MSCs derived from other tissue sources. The existence of 
MSCs in tendon tissue was first reported in 2003 [26]. Tendon-derived cell lines expressing 
tendon-phenotype related genes such as scleraxis, cartilage oligomeric matrix protein (COMP), 
and type I collagen (in addition to osteopontin and Runx2), were developed from transgenic 
mice.  Bi et al. (2007) identified and characterized a unique cell population, termed tendon 
stem/progenitor cells from mouse and human tendon samples [27]. These cells demonstrated 
universal stem cell characteristics of clonogenicity, multipotency and self-renewal capacity. This 
study also showed that the bioactivity of TDPCs, like other MSCs, is heavily dependent on their 
local environment/ matrix interactions (‘niche’). Comprehensively characterizing 
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stem/progenitor cells in tendons and their role in tendon responses to injury is paramount for 
developing effective regenerative therapies.  
            
In vitro Characteristics of TDPCs: 
TDPC isolation: TDPCs have been isolated from fetal [28] and adult human, murine [27], rat 
[29], lapine [30] and equine [31,32] tendons. TDPCs are typically isolated via collagenase type I 
digestion followed by low-density plating. Most studies have used an initial seeding density of 
5x102 cells/cm2, however the optimal seeding density for TDPC isolation has not been 
established. Cell surface epitope-based selection (CD90+, CD73+, CD105+ and CD45-) for TDPC 
isolation from tendon digests has also been attempted. However, this technique does not separate 
tenocytes and fibroblasts from TDPCs, as markers specific for tenogenic lineage are lacking 
[33,34]. Other techniques of TDPC isolation include cell migration from tendon explants [27], 
differential adhesion of isolated cells [32,35], colony isolation [30] and selective substrate 
adhesion to fibronectin [31]. No clear benefits of the latter techniques over standard low-density 
plating have yet been identified. Currently, enrichment of TDPCs relies on multiple passage sub-
culture, to enrich for rapidly and persistently proliferative stem cells from initial heterologous 
tendon digest populations [36].  
      
Donor age may influence the number, proliferative and multi-lineage capacities of TDPCs. The 
total number of TDPCs in aged rats decreased by 70% compared to young rats [37]. In human 
isolates, proliferation and clonogenicity of TDPCs from aged tendons was decreased although 
their multi-lineage potential was retained [38]. Age did not affect in vitro characteristics in 
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equine TDPCs [31], suggesting that species-specific differences in age-dependent in vitro 
characteristics of TDPCs exist.  
       
TDPCs have been isolated from rat and murine Achilles and patellar tendons, lapine Achilles 
tendon, human patellar, Achilles, rotator cuff and biceps tendons, and equine extensor and flexor 
tendons. Clear differences in the characteristics of TDPCs isolated from different tendons have 
not been demonstrated, but the number and biosynthetic activity of TDPCs are increased in 
response to physiologic loading and exercise, [39], and the stem/progenitor cell populations 
derived from the peritenon and tendon proper are distinct [40-42]. Tendon proper-derived 
TDPCs were more permissive for in vitro tenogenic differentiation than peritenon-derived 
progenitor cells. Further investigation into this aspect of TDPC biology is warranted, since these 
sub-populations may have distinct functions and efficacies in intrinsic and extrinsic tendon 
healing. 
  
In vitro expansion and proliferation: Using TDPCs to treat tendon injuries is dependent on 
efficiently expanding these cells to clinically relevant numbers while maintaining their 
‘stemness’ and therapeutic value during multiple passages. TDPCs, like other MSCs, proliferate 
more rapidly than terminally differentiated tenocytes during in vitro expansion [30]. Culturing 
human TDPCs in reduced oxygen conditions increases proliferation [43-45], metabolic rates and 
biosynthetic activities [40] but in one of these studies [43], 2% oxygen levels reduced their 
multi-lineage potency. Similarly, equine TDPCs isolated via low-density plating and cultured 
under hypoxic conditions had higher proliferation rates than TDPCs cultured in normoxic 
conditions [31]. The effect of passage on the in vitro characteristics of TDPCs has received little 
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attention, and the existing data is not consistent.  Zhang et al. (2010) reported that the 
proliferation of porcine TDPCs decreased as the passage number increased [44]. In contrast, Tan 
et al. (2012) found that the proliferation rate and colony-forming ability of rat TDPCs increased 
with subsequent passages [46]. More research will be necessary to clarify this issue and 
determine species-specific consequences of multiple passages on subsequent activities.  
 
Immunophenotypic profile: TDPCs share common stem cell markers identified in MSCs from 
other tissue sources. Specific markers that distinguish TDPCs from terminally differentiated 
tenocytes are poorly defined. TDPCs express CD44, CD90, CD146, CD73, Sca-1, Stro-1, 
nucleostemin, Oct-4, SSEA-4 and are negative for CD31, CD34, CD45, CD144, CD106 [27-
31,40,44]. These markers cannot distinguish TDPCs from other MSCs and some these MSC 
markers are, in fact, fibroblast markers (CD44 and CD90). On the other hand, certain markers 
that distinguish TDPCs from bone marrow MSCs have been identified. Murine and human 
TDPCs lacked CD18 expression, which is expressed by bone marrow MSCs [27]. CD106 is 
expressed by human and rat TDPCs but is absent in bone marrow MSCs.  
             
The specific source of TDPCs may also affect their immunophenotype. Approximately 90% of 
TDPCs from tendon proper expressed Sca-1 whereas only 70% of peritenon-derived TDPCs 
expressed this marker [41]. As expected, TDPCs isolated from peritenon had higher expression 
of CD133 (a pericyte marker) than TDPCs from tendon proper. A similar study found that 
TDPCs from peritenon were CD146+, CD34-; TDPCs from interstitial tissue were CD146-, 
CD34+; and TDPCs from tendon proper were CD146-, CD34-. All three populations were 
CD44+, CD31-and CD45 – [40]. These findings must be interpreted with caution as these results 
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were largely derived from rat patellar tendon-derived TDPCs and the study sample sizes were 
low. Further research addressing the regional immunophenotypic characteristics of TDPCs is 
required to understand the link between immunophenotype and clinical efficacy.  
         
Due to a relatively small proportion of progenitor cells in tendon, most studies analyze the 
immunophenotype of TDPCs after a short period of sub-culture. The immunophenotype of 
TDPCs, as with other MSCs, changes during in vitro passaging. One study reported the 
Expression of CD146, CD73 and CD90 in freshly isolated rat patellar TDPCs is lost after in vitro 
culture [46,47]. Kowalski et al. (2015) reported that although in vitro passaging altered the 
expression of CD34 and CD44 in the three sub-populations of TDPCs, their overall pattern of 
expression was unchanged [40]. These findings suggest that any protocol for TDPC selection 
based on immunophenotype will need to accommodate the alterations that occur with in vitro 
culture. 
 
Multipotency of Tendon-derived Progenitor Cells:  
In vitro differentiation: TDPCs, like other MSCs, are able to differentiate into adipogenic, 
osteogenic and chondrogenic lineages when exposed to appropriate stimuli (Figure 2.4). 
Allowing for inter-species variability, the reported in vitro tri-lineage differentiation potential of 
TDPCs isolated from healthy tendons has been inconsistent across studies. Earlier seminal 
studies characterizing TDPCs reported equivalent differentiation along adipogenic, osteogenic 
and chondrogenic pathways [26,27,48]. In contrast, more recent studies have reported restricted 
adipogenic capacity of TDPCs isolated from normal tendons [31,49]. In vitro culture conditions 
can also affect the differentiation potential of TDPCs. Hypoxia during in vitro culture enhanced 
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the differentiation capacity of human TDPCs [45] although equine TDPCs were unaffected by 
hypoxia [31]. Further, in vitro passage decreased the adipogenic and chondrogenic 
differentiation of TDPCs while their osteogenic capacity was increased [50].  
 
The comparative differentiation potentials of TDPCs and bone marrow MSCs have also been 
investigated. de Mos et al. (2007 and Randelli et al. (2013) demonstrated that the tri-lineage 
potential of TDPCs and bone marrow MSCs were similar [33,48], whereas Tan et al. (2012) 
showed that TDPCs had a higher adipogenic, osteogenic and chondrogenic potential than bone 
marrow MSCs [50]. TDPCs have higher BMP receptor expression and are more responsive to 
BMP-2-induced osteogenic differentiation than bone marrow MSCs [36]. 
       
Data on the influence of donor age on TDPC multipotency is not consistent. TDPCs isolated 
from aged rat tendon underwent adipogenesis more readily and expressed higher levels of 
adipogenic markers (PPARγ, leptin) than their younger counterparts, whereas the osteogenic and 
chondrogenic capacity of TDPCs was unchanged [37]. However, more recent study that 
compared activities of human hamstring and Achilles tendon-derived TDPCs did not identify an 
effect of donor age on tri-lineage differentiation characteristics of TDPCs [38,51]. It is likely that 
species- and donor site-specific differences in the respective TDPC populations contributed to 
the disparities in outcome. Regardless, the influence of age on TDPC activity requires further 
investigation, given that degenerative tendinopathy is more prevalent in older individuals. 
        
The in vitro differentiation potential of TDPCs isolated from healthy tendon tissue and 
pathological tissue are markedly different. TDPCs isolated from injured tendon had a higher in 
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vitro chondrogenic potential than TDPCs from normal tendon [52]. These cells were implicated 
in chondro-degeneration noted during tendon healing and were characterized as CD105- cells. A 
follow-up study by the same group demonstrated that in vitro culture of TDPCs isolated from 
injured tendon treated with IL-1b decreased their trilineage differentiation potential. Further 
research on this aspect of TDPC pathobiology is required to determine whether cells isolated 
from pathological tissue during reparative surgeries can be used for consequent cell-based 
therapies [53]. Further, given the detrimental effects of inflammatory cytokines on TDPC 
activities, it will be critical to define the optimal time (following injury) for cell delivery to avoid 
aberrant responses of stem cells implanted in an active inflammatory milieu.   
 
Aberrant TDPC Differentiation in Tendinopathy: Fatty degeneration, chondrogenic dysplasia 
and ectopic calcification within the repair tissue of chronically injured tendons are well-
documented [54-63]. Ectopic chondro-ossification in the mid-substance of Achilles and patellar 
tendons occurred as a consequence of endochondral ossification [63,64], reflecting a major 
phenotypic shift within the tendon cell population. The underlying pathogenesis for these 
metaplastic changes in chronic tendonopathy is poorly understood. Abnormal matrix deposition 
likely occurs from extrinsic cells that migrate to the site of injury [65] or from native tenocytes 
and/or TDPCs that undergo trans-differentiation to non-tenogenic phenotypes.  
 
Experimental evidence indicates that alterations in matrix components within tendon repair 
tissue can profoundly impact the phenotype of TDPCs. TDPCs isolated from the biglycan-
fibromodulin double knockout mice had increased collagen type II and aggrecan expression 
compared to wild-type TDPCs [27]. In vivo, TDPCs isolated from these mice formed bone in 
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addition to tendon-like tissue, while the wild type TDPCs formed tendon-like tissue only. Asai et 
al. (2014) showed that TDPCs in injured tendons trans-differentiate into chondrogenic cells and 
induce chondro-degenerative lesions [52]. The molecular pathogenesis of aberrant TDPC 
differentiation in tendinopathy has not yet been fully elucidated, but several recent studies have 
implicated inflammatory cytokines, TGF-β/BMP signaling, extracellular matrix changes and 
altered biomechanical stimuli in these phenotypic shifts.  
 
Inflammatory cytokines and biological factors: The pro-inflammatory cytokines IL-1β, IL-6 
and TNFα are up-regulated in both acute and chronic strain type injuries [66-68], inducing 
expression of inflammatory mediators Cox-2, PgE2, and collagenases MMP-1 and -13. All these 
factors are known to be involved in tendon matrix degradation [69]. TDPCs isolated from injured 
tendon and cultured in the presence of IL-1β irreversibly lose their tenogenic identity and 
increase their chondrogenic and osteogenic capacities [53].  
       
TGFβ signaling is critical to fibrosis and scar formation in connective tissues and has also been 
implicated in pathogenesis of tendon injury [57,70,71]. TGFβ signaling activity, from TGFβ-1 in 
particular, is increased in injured tendon, particularly in regions of chondrogenic metaplasia and 
heterotopic ossification [63,64]. Excessive TGFβ signaling also stimulates pro-inflammatory 
effects and tenocyte apoptosis [70]. TGFβ alters the metabolic activities of tenocytes during 
healing, increasing collagen secretion and consequent scar tissue formation, providing a 
therapeutic rationale for TGFβ signaling blockade. In support of this concept, attenuation of 
TGFβ signaling by targeting TGFβ-1, CTGF and Smad 3 with anti-sense oligonucleotides 
reduced scarring and adhesion formation in a murine flexor tendon repair model [72]. Further, 
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the chondro-degenerative lesions induced by injured TDPCs in healing tendons are dependent on 
TGFβ signaling [52].   
         
Chondro-osteogenic BMPs, such as BMP-2, BMP-4, BMP-6 and BMP-7, promote cartilage, 
bone and bone-tendon junction repair [73-77]. Several lines of evidence implicate dysregulation 
of BMP activity in tendinopathy as a cause of ectopic calcification. Ectopic overexpression of 
BMPs is observed in naturally occurring calcifying tendinopathy and experimental models of 
tendinitis [78,79], and intra-tendinous administration of rhBMP-2 results in ectopic calcification 
[80]. Murine TDPCs exposed to BMP-2 during in vitro culture prior to subcutaneous 
implantation into immuno-compromised mice generated enthesis-like elements comprised of 
both tendon-like and osseous tissues [27].  
 
Altered tendon matrix composition: Disorganized collagen matrix, increased non-collagenous 
ground substance and an increased number and rounded morphology of the tenocytes are 
hallmarks of injured tendon [81,82]. During the healing process of experimental and naturally 
occurring tendinitis, the levels of large proteoglycans and sulfated glycosaminoglycans 
(characteristic of cartilage matrix) increase within tendon matrix [62,83-85]. These changes 
reduce the elasticity and tensile strength of the repair tissue. Proteoglycans such as biglycan, 
decorin, fibromodulin and lumican, although constituting a very small portion of tendon ECM, 
are active participants in collagen fibrillogenesis [86-89] and can also bind and sequester growth 
factors such as TGFβ and IGF-I [52,70,90-92] to modulate TDPC activities.  
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Altered tendon biomechanics: TDPCs, like terminally differentiated tenocytes, are sensitive to 
repetitive tensile loading in vitro [30,93]. Short-term treadmill exercise increased the yield of 
TDPCs from murine Achilles and patellar tendons. Further, the TDPCs isolated from exercised 
mice had higher biosynthetic activities than control mice. In vitro exposure to 4% tensile strain 
promoted tenogenic differentiation, whereas 8% tensile strain induced osteogenic differentiation 
[30]. TDPCs exposed to in vitro mechanical loading increased BMP-2 expression and had a 
higher osteogenic potential compared to unloaded TDPCs [93]. A recent study demonstrated that 
applying in vitro biaxial mechanical stress induces the expression of the proteoglycans, 
fibromodulin, lumican and versican in TDPCs [94]. These findings provide a mechanistic 
explanation for ectopic calcification that occurs as a result of mechanical overloading. The 
combination of excessive loading, BMP up-regulation and alterations in non-collagenous protein 
expression could generate conditions favoring TDPC chondro-osteogenesis, at the expense of 
tenogenic differentiation.  
 
Applications of Tendon-derived Progenitor Cells in Tendon Regeneration: 
Stem cell implantation has improved tendon healing in most studies (reviewed in 10,11,14,15]. 
Accepting the experimental benefits of stem cell-based therapies, several factors must be 
considered while choosing a particular cell type to treat tendon injuries. The tissue source must 
be easily accessible with acceptable donor site morbidity. The requirements for vitro 
manipulation (expansion and phenotypic modulation) should be minimized, to mitigate the risks 
of contamination and ‘chain of custody’ lapses. Finally, the phenotypic and reparative activities 
of the therapeutic cell type should closely match the target tissue. In this respect, tenogenically-
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committed stem/progenitor cells derived from tendons seem more appropriate for tendon 
regeneration than MSCs obtained from other tissue sources.  
 
In vitro evidence supporting TDPCs for tendon regeneration: 
Several recent studies have evaluated the tenogenic potential of TDPCs under in vitro conditions. 
Acellular tendon has been used in tissue-engineering studies as a scaffold in cell-based 
approaches for flexor tendon injuries in murine models [95,96]. Decellularization of tendons was 
carried out by freeze-thaw cycles followed by trypsin digestion. Co-culturing TDPCs with 
acellular tendon matrix in vitro significantly increased their tenogenic marker expression and 
subsequent tenogenic differentiation. This acellular tendon-matrix model has been used by our 
group for comparative analyses of equine TDPCs and bone marrow for tendon healing [97,98]. 
TDPCs were more viable and showed superior integration into acellular tendon matrices than 
bone marrow MSCs (Figure 2.5). In addition, TDPCs had significantly higher collagen and 
proteoglycan synthesis levels than bone marrow MSCs. A follow-up study showed that 
supplementing FGF-2 during monolayer expansion of TDPCs potentiated the biosynthetic 
activities of TDPCs compared to bone marrow MSCs during in vitro culture with pulverized 
acellular tendon matrix [35]. Human fetal TDPCs cultured in aligned nanofibrous scaffold 
supported tenogenesis and suppressed osteogenic differentiation [28]. Collectively, these results 
indicate that TDPCs respond to tendon matrix components by adopting a biosynthetically active 
tenogenic phenotype, supporting the strategy of implanting these cells into healing tendon 
lesions. 
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In Vivo Evidence Supporting TDPCs for Tendon Regeneration: 
The benefits of cell-based treatments for experimental tendon defects were first reported in 2002. 
Autologous tenocyte constructs were used to bridge partial flexor tendon defects in adult 
chickens [99].  Fourteen weeks following implantation of tenocytes, the histologic structure and 
biomechanical properties of the tenocyte-treated tendons were significantly improved compared 
to the untreated controls. Since the discovery and characterization of TDPCs, several studies 
have evaluated the reparative activity of TDPCs in in vivo models of tendon injury. These 
studies are summarized in Table 2.1.  
          
Ni et al. (2012) were the first to investigate the in vivo healing characteristics of TDPCs in a rat 
patellar tendon window defect model [100]. GFP-labeled TDPCs in a fibrin glue matrix were 
injected at the defect. TDPC numbers at the site of injection decreased over time and were 
completely absent by four weeks after implantation. TDPC implantation improved the histologic, 
biomechanical and ultrasonographic characteristics of patellar tendon healing. No ectopic bone 
formation was detected at 4 and 16 weeks post-injury, which were the end-points of this two-part 
study. A subsequent study by the same group evaluated the effect of rat patellar tendon-derived 
TDPCs transduced with scleraxis (SCX) in the same model [101]. The histological and 
biomechanical characteristics of TDPC-Scx treated tendons were significantly better than 
tendons treated with TDPCs transduced with empty viral vector, suggesting that genetically 
priming TDPCs for tenogenic differentiation is clinically beneficial, although an alternative to 
viral delivery will likely need to be developed prior to approval for clinical applications.  
         A recent study by our group evaluated the effect of autologous TDPCs in a collagenase-
induced equine flexor tendinitis model [102]. The TDPCs were implanted four weeks after 
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tendinitis induction, and improved the biomechanical and histological characteristics of the 
tendons, 12 weeks following administration. The biochemical and transcriptional outcomes were 
not significantly influenced by TDPC injection. Similar to the findings of Ni et al. (2012) [100], 
TDPCs were not detected at the injection sites beyond 4 weeks after treatment. Significant 
improvements in collagen micro-architecture have also been reported in this equine model, 
following bone marrow MSC [103], adipose-derived MSC [104] and fetal-derived embryonic 
stem cell [105] administration. The biomechanical consequences of these other progenitor types 
have yet to be determined and the relative merits of these stem cell populations for tendon repair 
have yet to be defined in direct comparative studies.  
           
Accepting the multipotency of TDPCs, priming TDPCs for tenogenic differentiation during in 
vitro culture and expansion has been investigated to avoid abnormal matrix deposition within the 
healing tissue [106]. Connective tissue growth factor (CTGF) is highly expressed during early 
stages of tendon repair [107]. In addition, CTGF stimulates tenogenic differentiation of TDPCs 
in vitro, when supplemented with ascorbic acid [108].  Rat patellar tendon-derived TDPCs were 
cultured with CTGF and ascorbic acid for two weeks to produce a thin cellular sheet, before 
being transplanted into patellar tendon window defects [109]. The biomechanical and histologic 
characteristics of the TDPC-treated tendons at 2, 4, and 8 weeks were improved compared to un-
treated controls. A recent follow-up study by the same group included an additional experimental 
group in which untreated TDPCs in a fibrin glue matrix (i.e cultured without CTGF and ascorbic 
acid) were implanted into the patellar tendon window defect [110]. The biomechanical, 
histological and ultrasonographic characteristics of tendons defects treated with TDPCs that were 
 
20 
exposed to CTGF and ascorbic acid were significantly better than defects treated with control 
TDPCs, suggesting that pre-implantation ‘priming’ of TDPCs will be clinically beneficial.  
        
Autologous products like platelet-rich plasma (PRP) can also be administered with TDPCs to 
enhance tendon repair. Intralesional PRP administration alone has improved the overall healing 
characteristics of repair tissue in experimental models of tendinitis [111,112].  In vitro, platelet-
rich clot releasate stimulates tenogenic differentiation of TDPCs while inhibiting osteogenic 
differentiation [113]. TDPCs and PRP synergize to stimulate collagen gene expression of healing 
rat Achilles tendons [114]. In a follow up study by the same group, passage 2 TDPCs were 
cultured with platelet-rich clot releasate for 3 days prior to in vivo administration [115]. TDPCs 
supplemented with PRP prior to intralesional administration significantly improved the overall 
healing characteristics of the Achilles tendon compared to control TDPCs. These findings 
support the hypothesis that PRP likely augments the local trophic factor synthesis and cytokine 
modulatory effects of TDPCs and improves reparative effects, while also acting as a bio-
compatible delivery vehicle.  
  
TDPCs in Tissue Engineering: 
TDPC activities are heavily influenced by extracellular matrix. Given that there is gross 
disruption of tendon matrix in acute injuries and major changes in extracellular matrix 
composition in chronic tendinopathy, incorporating TDPCs in an appropriate ‘teno-inductive’ 
scaffold may improve tissue repair, in comparison to direct injections of TDPCs. Biological 
scaffolds seeded with differentiated tenocytes and bone marrow MSCs have improved repair of 
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tendon defects in several in vivo models [reviewed in 13]. Similar approaches using TDPCs have 
been evaluated in a few studies.  
          
Zhang et al. (2009) prepared decellularized matrix by pulverizing and nuclease-digesting tendon. 
This matrix promoted proliferation and tenogenic differentiation of human and rat patellar 
tendon-derived TDPCs in vitro [95]. Subsequently, TDPCs cultured with decellularized tendon, 
or TDPCs alone were implanted subcutaneously, along the dorsal midline, and into patellar 
tendon window defects of nude mice. Interestingly, TDPCs cultured with tendon matrix 
synthesized neo-tendon tissue whereas naïve TDPCs did not form recognizably tendon-like 
tissue at either site. A decellularized matrix prepared from dermal fibroblasts was used to support 
rat and human patellar tendon-derived TDPCs for one week prior to in vivo implantation in a 
similar in vivo model [116]. Co-culturing TDPCs with dermal fibroblast-derived matrix 
promoted tenogenic differentiation in vitro and neo-tendon formation in vivo, whereas these 
effects were not seen with control TDPCs. Given that matrices from both tendinous and non-
tendinous sources support proliferation and tenogenic differentiation of TDPCs, an appropriate 
bio-matrix could optimize the therapeutic value of these cells after in vivo delivery, although 
implantation of semi-solid cell-matrix composites is clearly more invasive and complicated than 
percutaneous injection.  
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Table and Figures: 
 
 
 
Table 2.1: Summary of TDPC-based tendon repair in in vivo models. 
  
TENDON SPEC- 
IES 
MODEL SOURCE OF 
TDPCs 
IN VITRO 
CULTURE 
AND EXPANSION 
VEHICLE 
USED 
DURA-
TION 
OF 
THE 
STUDY 
Ref. 
Patellar  Rat Patellar tendon 
window defect 
Rat patellar 
tendon-
derived 
Low density plating Fibrin glue 4  
weeks 
[104] 
Patellar Rat Patellar tendon 
window defect 
Rat patellar 
tendon-
derived 
Low density plating Fibrin glue 16 
weeks 
[98] 
Patellar Rat Patellar tendon 
window defect 
Rat patellar 
tendon-
derived 
Low density plating  
+ CTGF (25 ng/mL) 
and Ascorbate (25 
uM) 
Scaffold-
free cell 
construct 
8  
weeks 
[112] 
Patellar Rat Patellar tendon 
window defect 
Rat patellar 
tendon-
derived 
Low density plating 
+/- CTGF (25 ng/mL) 
and Ascorbate (25 
uM) 
Fibrin glue 16 
weeks 
[113] 
Patellar Rat Patellar tendon 
window defect 
Rat patellar 
tendon-
derived 
Low density plating 
and lentiviral-induced 
Scleraxis 
overexpression 
Fibrin glue 8 weeks [119] 
Patellar Rat Patellar tendon 
window defect 
Rat and 
Human 
patellar-
tendon 
derived 
Low density plating 
+ in-vitro culture with 
decellularized tendon 
matrix 
Tendon 
Matrix gel  
8 weeks  [99] 
Patellar Rat Patellar tendon 
window defect 
Rat and 
Human 
patellar-
tendon 
derived 
Low density plating 
+ in-vitro culture with 
dermal fibroblast 
matrix 
Dermal 
fibroblast 
matrix 
8 weeks [120] 
Achilles Rat Achilles 
transection 
Rat Achilles-
derived  
Low density plating Collagen 
sponge 
2 weeks [116] 
Achilles Rat Collagenase Rat Achilles- 
derived  
Low density plating + 
10% PRP releasate to 
P2 TDPCs for 3 days 
PRP 8 weeks [117] 
SDFT  Horse Collagenase Lateral digital 
extensor 
tendon-
derived 
Differential adhesion 
selection 
Saline 12 
weeks 
[105] 
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Figure 2.1: Schematic representation of hierarchical structure in tendons. 
 
Figure 2.2: Hematoxylin and eosin stained, bright-field microscopy image of a longitudinal 
section of normal equine tendon. Scale bar = 100 microns. 
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Figure 2.3: Picro-Sirius Red stained, polarized light microscopy image of a longitudinal section 
of (A) normal and (B) chronically injured (16-weeks post collagenase-injection) equine 
superficial digital flexor tendon. Scale bar = 100 microns. 
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Figure 2.4: Trilineage differentiation of equine TDPCs. (A) Oil-Red-O staining of TDPCs after 
14 days in adipogenic medium. (B) Alizarin Red staining of TDPCs after 14 days in osteogenic 
medium. (C) Toluidine blue-stained TDPC pellet at day 20 in chondrogenic medium. In all 
panels, bar = 100 microns.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5: (A) TDPCs and (B) bone marrow MSCs seeded on acellular tendon matrices 
demonstrate differential colonization of tendon explants and some penetration by TDPCs into the 
underlying matrix. Scale bar = 100 microns. 
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CHAPTER 3: DIFFERENTIAL ADHESION SELECTION FOR ENRICHMENT OF      
TENDON-DERIVED PROGENITOR CELLS DURING IN VITRO CULTURE 
This chapter was accepted for publication as an original research article in the journal Tissue 
Engineering Part C Methods. 2016 August 1, [EPub ahead of print].b  
 
Introduction:  
 
Tendinitis is a common career-limiting injury in athletes. In general, tendons have a poor healing 
capacity, and the resultant repair tissue is biomechanically inferior to healthy tendon [1,2]. Re-
injury is common despite prolonged rehabilitation [3]. Cell-based therapies show promise to 
improve the quality of tendon repair and consequent functional restoration. The efficacy of intra-
lesional mesenchymal stem cell (MSC) administration for tendon healing has been evaluated in 
experimental models of tendinitis. These studies have consistently have demonstrated improved 
histologic and biomechanical repair indices [4-7]. 
           
Although the benefits of MSC-based therapies for tendinitis and other musculoskeletal injuries 
have been well established, their clinical use depends on identifying a suitable cell source, 
isolating a homogenous progenitor population, and efficiently expanding the cells to clinically 
applicable numbers while maintaining therapeutic efficacy. Currently, several techniques to 
enrich MSCs from primary cell isolates have been developed. These include cell separation 
based on size and shape [8,9], expansion from initial low density plating [10], differential 
attachment to plastic or other substrates [11,12] and/or specific cell surface markers [13-15].               
 
b Durgam, S., Schuster, B., Cymerman, A., Stewart, A., Stewart, M. 2016. Differential adhesion selection for 
enrichment of tendon-derived progenitor cells during in vitro culture. Tissue Engineering Part C Methods, August 1, 
[EPub ahead of print].  
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Tendon-derived progenitor cells (TDPCs) constitute a promising resource for tendon 
regeneration [16,17]. Several recent studies have characterized TDPCs on the basis of previously 
established MSC cell surface markers [18-20]. In all these studies low-density plating and 
subsequent colony formation was used to isolate TDPCs. Immunophenotyping TDPCs and 
selective enrichment using MSC markers has proved to be problematical as markers exclusive to 
the tenogenic phenotype are limited [21,22]. Currently, isolation of homogeneous TDPCs relies 
on serial passage sub-culture, to enrich for rapidly and persistently proliferative stem cells from 
initial heterologous tendon digest populations. Time-dependent adherence, or ‘preplating’, is a 
marker-independent isolation method, which segregates rapidly adherent fibroblasts from the 
less adherent progenitor cells. This approach has been successfully used to isolate stem cells 
from skeletal and cardiac muscle tissues [23-25]. Muscle and tendon tissues are both 
mesenchymally derived tissues with relatively low cell densities and a hierarchically arranged, 
predominantly fibrillar extracellular matrix [26,27]. Further, the cellular compartments of both 
tissues contain heterogeneous populations with very few progenitor cells [18,23]. The objective 
of this study was to determine if preplating enriches TDPCs from tendon digests prior to 
monolayer expansion. To test this hypothesis, preplate-selected TDPC sub-populations were 
characterized via immunophenotyping and standard trilineage differentiation assays. 
 
Methods:  
TDPC Isolation and Preplating: All procedures were approved by the University of Illinois 
Institutional Animal Care and Use Committee. Hindlimb lateral digital extensor (LDE) tendon 
was harvested from four young adult horses (2- 4 years of age) euthanized for reasons unrelated 
to musculoskeletal disease. A 1-2 cm length of LDE tendon specimen was diced into 0.25-cm3 
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pieces and digested in 0.2% collagenase (Worthington) in DMEM supplemented with 2% fetal 
bovine serum (Gemini Biomedicals) at 37oC for 16 hours [28,29]. The cells were isolated by 
filtration and centrifugation and the cells were seeded at 500 cells/cm2 in monolayer cultures in 
high-glucose DMEM supplemented with 20% fetal bovine serum, 37.5 µg/ mL of ascorbic acid, 
300 µg of L-glutamine/mL 100 U of sodium penicillin/mL, and 100 µg of streptomycin 
sulfate/mL. TDPCs were isolated using a differential attachment protocol established for 
isolating stem cells from skeletal muscle digests [23-25]. Primary cells from tendon digests were 
seeded onto adherent flasks, and the culture medium containing unattached cells was serially 
transferred to fresh culture flasks every 12 hrs, on seven occasions. The cells that adhered during 
initial plating were designated as TPP0; and the cells that adhered after 36 (third transfer) and 84 
hrs (seventh transfer) were designated as TPP3 and TPP7, respectively. Subsequently, TDPCs 
obtained from TPP0, TPP3 and TPP7 were expanded in monolayers for two passages and used 
for subsequent analyses.  
 
Monolayer expansion and cell proliferation: TDPC fractions isolated by preplating were 
trypsinized at approximately 80% confluency. Viability was determined via trypan blue 
exclusion and the resultant cells were seeded at 1 x 104 cells/cm2 and expanded in monolayer 
cultures in high-glucose DMEM supplemented with 10% fetal bovine serum, 37.5 µg/ mL of 
ascorbic acid, 300 µg of L-glutamine/mL, 100 U of sodium penicillin/mL, and 100 µg of 
streptomycin sulfate/mL (complete DMEM) incubated at 37oC in 4% CO2, and 95% humidity 
conditions [28]. Passage 0 TDPCs were counted and replated at 10,000 cells/cm2 and expanded 
in monolayers for two passages. Cell proliferation during first and second passages (P1 and P2) 
of each TDPC fraction was calculated as population doublings using the formula: Log2 
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(harvested cell number/seeded cell number). Population doubling times during P1 and P2 of each 
TDPC fraction were calculated by dividing the time of each passage by the corresponding 
population doubling value. Cells obtained from confluent passage 2 monolayers of TPP0, TPP3, 
TPP7 (passage 3 TDPCs) were used for immunophenotyping and differentiation assays.  
 
Flow Cytometry and Immunophenotyping: Third passage TDPCs from TPP0, TPP3, TPP7 
were used for single-color flow cytometry. Aliquots of 1 x 106 TDPCs were fixed in 4% 
paraformaldehyde and then blocked with 1% BSA in high-glucose DMEM for 20 minutes. Cells 
were washed in PBS and resuspended in either fluorescent conjugated or unconjugated primary 
antibodies and incubated at 4oC for 30 minutes. Flow cytometry was used to evaluate the MSC 
immunophenotype (CD29, CD44 and CD90) during monolayer expansion, following previously 
published protocols [30]. CD45 was included as a negative control for hematopoietic 
progenitors. The following antibodies were used according to the manufacturers’ 
recommendations: anti-human conjugated anti-CD29-Alexa 488 (BioLegend); anti-horse 
conjugated anti-CD44-RPE (AbD Serotec, BioRad); anti-horse non-conjugated anti-CD90-Alexa 
647 (Accurate Chemical and Scientific Corporation) and anti-human conjugated anti-CD45-
Alexa 488 (AbD Serotec, BioRad) [30]. The following filters were used in a flow cytometry 
analyzer (Accuri C6, BD Biosciences) to isolate the emission wavelength of the conjugated 
fluorochromes: FL-1 (510 nm and 545 nm wavelengths of light) for CD29 (519 nm emission) 
and CD45 (519 nm emission), FL-2 (560-580 nm wavelength) for CD44 (578 nm emission) and 
FL-4 (665-695 nm wavelength) for CD90 (668 nm emission). After the emission analysis on 
“FCS express (Flow Research Edition)”, data were expressed as ‘percentage of deviation from 
the control antibody groups’. Bone marrow-derived MSCs were used as reference controls. Cells 
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in the absence of antibody and in the presence of secondary antibody only were used as controls. 
A threshold gating out at least 95.5% of control cells was used.  
 
Tenogenic Gene Expression: Three million third passage TDPCs from TPP0, TPP3 and TPP7 
were stored for RNA isolation prior to trilineage differentiation experiments. Basal expression of 
tenogenic genes, scleraxis (Scx) and tenomodulin (Tnmd) was assessed by quantitative PCR, as 
detailed below. 
 
Trilineage differentiation and phenotypic staining:  
Osteogenic culture: Passage 3 TDPCs from TPP0, TPP3 and TPP7 were plated at 5 x 103 
cells/cm2 in 6-well plates and cultured in complete DMEM until they reached 80 % confluence. 
Complete DMEM was then substituted with osteogenic media (complete DMEM supplemented 
with 10 mM β glyceraldehyde-3-phosphate, 50 µg/mL ascorbic acid, 100 ηM dexamethasone). 
The media were replaced every 3 days [11,20]. The cultures were maintained for 14 days.  
         Alizarin Red staining was used to assess mineralized matrix deposition. The cell-matrix 
layer was washed with PBS and fixed with 70% ethanol, and stained with 2% Alizarin R stain 
for 10 mins. Low-magnification (10x) images were obtained prior to osteogenic differentiation 
and at days 7 and 14 of osteogenic culture. Up-regulation of osteogenic genes was also assessed 
by quantitative PCR, as detailed below. 
 
Adipogenic culture: Passage 3 TDPCs from TPP0, TPP3 and TPP7 were cultured in 6-well 
plates with complete DMEM until they reached 80% confluence. Complete DMEM was then 
substituted with adipogenic media (high-glucose DMEM containing 10% rabbit serum, 100 U of 
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sodium penicillin/mL, 100 µg of streptomycin sulfate/mL and supplemented with 1 mM 
dexamethasone, 100 mM indomethacin, 10 mg/mL insulin, and 500 mM 
isobutylmethylxanthine) [11,20]. Media were replaced every 2 days. These cultures were 
maintained for 10 days.  
 
Oil-Red-O staining of monolayers was used to detect intracellular lipid accumulation. Cell 
monolayers were washed with PBS, fixed with 70% ethanol, and stained with 0.3% Oil Red O 
stain for 1 hour. Low- (10x) and high-magnification (50x) images were obtained prior to 
adipogenic differentiation and at days 3 and 10 of adipogenic culture. Up-regulation of 
adipogenic genes was also assessed by quantitative PCR, as detailed below. 
 
Chondrogenic culture: Pellet cultures were established in microcentrifuge tubes from passage 3 
TDPCs by resuspending 5 x 105 cells/mL in chondrogenic media (high-glucose DMEM 
supplemented with 100 ηM dexamethasone, 25 µg/ml ascorbic acid, 10 ηg/ml TGF-β1, 1% ITS 
media supplement), and pelleting 500 µl aliquots of the cell suspensions at 400 rcf [11,20,30]. 
Chondrogenic cultures were maintained for 20 days. Media were replaced every 3 days.  
        
Representative pellet sections were stained with toluidine blue to assess sulfated 
glycosaminoglycan (sGAG) deposition [30]. After 20 days, cell pellets were fixed in 4% 
paraformaldehyde, dehydrated and embedded in paraffin. Six micron-thick sections were stained 
with toluidine blue. High-magnification (50x) histological images were acquired with LEICA 
Q500MC microscope (Leica Cambridge Ltd). Up-regulation of chondrogenic genes was also 
assessed by quantitative PCR, as detailed below. 
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RNA Isolation and Quantitative RT-PCR: Total RNA was isolated using a previously 
described protocol [28,30]. The samples were homogenized in a guanidinium thiocyanate-
phenol-chloroform solution reagent (TRIzol, Invitrogen) according to manufacturer’s suggested 
protocol. RNA isolation from the chondrogenic pellets included the high-salt precipitation 
variation recommended by the manufacturer, to minimize co-precipitation of proteoglycans [30]. 
The resultant pellet was purified using RNeasy silica columns that included on-column DNase 
digestion. One µg of RNA from each sample was reverse-transcribed (Superscript II, Invitrogen) 
using oligo(dT) primers. Equine gene-specific primers were designed from published sequences 
in Genbank, and using ClustalW multiple sequence alignment (available at www.ebi.ac.uk) 
(Table 3.1). Primer specificity was confirmed by cloning and sequencing the amplicons during 
optimization experiments, as previously described [28,30]. PCR amplifications were catalyzed 
by Taq DNA polymerase (BioRad iCycler, Bio-Rad Laboratories) in the presence of Sybr green. 
Relative gene expression was quantified using the 2-∆∆CT method, normalized to expression of the 
reference gene, elongation factor-1α (EF1α) [31].   
 
Statistical Analysis: The normality of distribution of quantitative data (relative mRNA 
expression) was confirmed using the Kolmogorov-Smirnov test using SigmaStat 4 software 
(Systat Software). Data are expressed as ‘mean ± standard error’. One-way ANOVA was used to 
assess the effect of preplating on cell proliferation and differentiation, in the three fractions of 
TDPCs (TPP0, TPP3, TPP7). A p value of ≤ 0.05 was considered significant. 
 
 
 
 
43 
Results: 
Cell Culture and Proliferation: The time from initial plating of each preplated TDPC 
subpopulation to 80% confluence was significantly less in TPP0 (4 + 0.9 days; p = 0.034) than in 
TPP3 (9.8 + 0.9 days) and TPP7 (12.3 + 1.2 days). In addition, the more slowly adherent TDPC 
sub-populations were quiescent for the first 5-6 days after transfer, prior to cell division and 
colony formation. Population doubling time and population doublings during P1 and P2 were not 
significantly different between the TDPC fractions (Figure 3.1). 
 
Immunophenotype:  More than 90% of cells from all TDPC fractions were immunopositive for 
CD29, CD 44 and CD90; surface markers that characterize equine MSCs. All fractions of 
TDPCs were negative for the hematopoietic marker, CD45 (Figure 3.2). There were no 
significant differences (p = 0.7) in the immunophenotypes of TPP0, TPP3 and TPP7.  
Tenogenic Gene Expression: The basal mRNA expression of tenogenic markers, Scx and Tnmd 
was similar in all TDPC fractions (p > 0.1) (Figure 3.3).  
 
Tri-lineage Differentiation:  
Osteogenesis: Alizarin Red staining of the mineralized matrix in day 7 osteogenic TDPC 
cultures showed minimal stain uptake in all fractions. By day 14, intense staining of mineralized 
nodules, indicative of robust osteogenic differentiation, was evident in all TDPC fractions 
(Figure 3.4). There were no noticeable differences in the intensity of Alizarin Red stain uptake 
between the TDPC fractions. Basal mRNA expression of osteogenic transcription factors osterix 
and Runx2 was similar in all TDPC fractions prior to osteogenic differentiation. In osteogenic 
medium, expression of osterix and Runx2 transcripts was significantly increased (10-12 fold; 
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p<0.05) by day 14 in all TDPC fractions and the expression was not significantly different 
between them. At day 14 of osteogenic induction, changes in mRNA levels of genes linked to 
osteogenic phenotype (osterix, osteonectin, alkaline phosphatase) corroborated the Alizarin Red 
staining outcomes. Expression of osterix, Runx2, osteonectin and alkaline phosphatase at day 14 
of osteogenic culture was not significantly (p=0.6) different between the TDPC fractions (Figure 
3.4).  
 
Adipogenesis: Oil-Red-O staining of adipogenic cultures showed intracellular lipid droplet 
deposition in all TDPC fractions at day 3 that was higher at day 10 (Figure 3.5). Basal mRNA 
expression of the adipogenic transcription factor PPARγ was similar in all TDPC fractions. 
Adipogenic culture medium stimulated a marginal increase (2-3 fold) in PPARγ mRNA 
expression by day 10 in all three TDPC fractions; this increase was not significant (p=0.4). 
Changes in expression of adipogenic genes (PPARγ, FABP-4 and adiponectin) were not 
consistent (Figure 5B). Expression of adiponectin mRNA at day 10 of adipogenic culture was 
significantly (p=0.042) higher in TPP7 compared to TPP0 and TPP3; however, there was no 
significant difference in expression of FABP-4 in the three TDPC factions at day 10 of 
adipogenic culture (Figure 3.5).  
 
Chondrogenesis: Toluidine blue staining intensity of day 20 chondrogenic pellets was minimal 
in all three TDPC fractions indicating low sulfated glycosaminoglycan (sGAG) content within 
the pellets (Figure 3.6).  Basal mRNA expression of Sox-9 was similar in all TDPC fractions. As 
expected, chondrogenic stimulation significantly up regulated Sox-9 mRNA expression at day 20 
compared to baseline, but Sox-9 expression was not significantly (p=0.31) different between the 
 
45 
three TDPC fractions. Chondrogenic matrix gene transcripts (collagen type II and aggrecan) 
were significantly (p=0.002) up regulated at day 20 of chondrogenic stimulation compared to 
baseline in all TDPC fractions (Figure 3.6). 
 
Discussion:  
This study investigated the value of preplating for TDPC enrichment from tendon digests. We 
hypothesized that a differential attachment preplating screen would enrich for TDPCs in the 
more slowly adherent fraction(s). Accepting the marked differences in initial seeding densities of 
the primary cultures, preplating and subsequent monolayer expansion did not alter the 
growth/proliferation or immunophenotypic characteristics of the TDPC sub-populations. Basal 
expression of tenogenic markers was similar across the preplate fractions and the osteogenic, 
adipogenic and chondrogenic differentiation capacities of the three TDPC fractions were also 
similar. These outcomes do not support the hypothesis. 
         
Time to confluence was significantly shorter for TPP0 cultures, compared to TPP3 and TPP7. 
This finding was expected, given that a large proportion of the primary isolates attached during 
the first preplate. There were substantially fewer unattached cells after the first serial plating for 
subsequent transfers. The population doubling and population doubling times in subsequent 
passages were similar across the TDPC fractions, indicating that the ‘per cell’ proliferative 
capacities of the sub-populations were similar; consistent with results obtained for muscle-
derived stem cells isolated via similar protocols [24,25]. Initial quiescence and heterogeneity in 
colony-forming units noted in this study during in-vitro isolation have also been reported in both 
mouse and human TDPCs [18] and is a common feature of MSCs from other tissue sources.  
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Allowing for species variations in stem/progenitor cell immunophenotypes, the cell surface 
marker profiles of equine TDPCs in our study were similar to other studies [11,20]  and were 
characteristic of equine MSCs (CD29+, CD44+, CD90+, and CD45−) [30,32,33]. Preplating and 
subsequent monolayer expansion did not influence immunophenotype. As with this study, 
preplated skeletal muscle-derived stem cell populations did not differ in their MSC surface 
marker profile; however, preplating did enrich cells expressing markers specific to myogenic 
stem cells [23,24,34]. Scleraxis expression did not differ in the TDPC preplate groups in this 
study; further, unpublished data from our group indicate that Scx expression in TDPCs and bone 
marrow-derived MSCs (from the same donors) is equivalent under basal conditions. The 
transcriptional regulation of tenogenesis is less well characterized than for myogenesis or several 
other mesenchymal lineages, and Scx expression, by itself, might be inadequate as a selection 
marker [35]. In support of this possibility, equine TDPCs exhibit several tenogenic 
characteristics more strongly than their bone marrow-derived counterparts in in vitro models, 
despite highly similar basal profiles [28,36,37]. 
        
Basal expression and induction profiles of osteogenic-, adipogenic- and chondrogenic-lineage 
genes in response to respective in vitro stimuli were similar in all TDPC fractions. However, the 
overall osteogenic, adipogenic and chondrogenic capacities of TDPCs were markedly different. 
All TDPC fractions underwent robust osteogenic differentiation, evident in both matrix staining 
and gene expression profiling. The induction of transcriptional adipogenic markers was 
inconsistent. PPARγ was only modestly up-regulated (approximately two-fold), while 
adiponectin induction was the only parameter assayed in this study that was responsive to 
preplating, exhibiting increased expression in later preplate sub-populations.   In marked 
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contrast, there was a significant (over three logs) increase in FABP-4 expression above baseline 
expression. These somewhat contradictory results indicate that the indices of adipogenesis 
addressed in this study are not transcriptionally linked, and emphasize the value in evaluating 
several phenotypic indicators in differentiation studies. Similarly, chondrogenic differentiation of 
TDPCs was less impressive than seen in other equine progenitor populations [30,38]. It is not 
clear from the outcomes of the current study whether the impressive osteogenic capacity of 
TDPCs is an intrinsic property of these cells or is an aberrant consequence of extensive in vitro 
proliferation. TDPC-mediated ectopic ossification has been reported during tendon healing 
[39,40], providing support for the former possibility. The restricted adipogenic and chondrogenic 
profiles of TDPCs observed in our study are consistent with other studies that characterized 
TDPCs isolated from healthy tendon via low-density plating [41] and specific substrate adhesion 
[11]. Fatty and mucoid degeneration [42,43], chondro-dysplasia [44,45] and ectopic ossification 
[39,40]  have been reported in both naturally occurring and experimental models of tendinitis. 
These changes reflect aberrant differentiation of progenitor cells and/or transdifferentiation of 
tenocytes within the tissue. Although the specific mechanism(s) that generates these aberrant 
phenotypes is undefined, it is likely that the differentiation of TDPCs under inflammatory/ 
healing and homeostatic conditions differ widely. In this respect, TDPCs isolated from healthy 
tendons with a restricted differentiation potential may be particularly suitable for cell-based 
therapies, provided a suitable source with minimal donor-site morbidity can be identified.  
 
The developmental origin of TDPCs is largely unknown and research in this area is ongoing. 
Although markers specific for tenogenic lineage (tenomodulin, scleraxis, mohawk) have been 
identified, their expression is not limited to tenogenic cells and they are not particularly useful 
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for cell isolation/selection protocols [21]. Other techniques of MSC isolation such as selective 
substrate adhesion, hypoxic conditions during in-vitro culture also did not enrich for TDPCs [11]. 
Although the results of this study indicate that preplating confers no clear benefit for TDPC 
enrichment, these outcomes and the results of related studies indicate that ‘whole tendon digest’ 
cell stocks are of significant therapeutic value for tendon repair [16,29,46].  
 
Conclusion:  
 In conclusion, differential adherence preplating did not enrich equine TDPC isolation during in 
vitro culture and monolayer expansion. Preplating did not alter the in vitro growth/proliferation 
characteristics of TDPCs. The immunophenotype and trilineage differentiation potential of the 
three TDPC fractions assessed in this study was similar. Overall, TDPCs had a robust osteogenic 
capacity and a minimal adipogenic and chondrogenic capacity. The results of this study indicate 
that whole digest tendon-derived cell stocks are adequate for enrichment of progenitor cells via 
monolayer expansion.  
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Table and Figures:  
 
Gene  Sequence Amplicon 
(bp) 
Scleraxis  
(Scx) 
S 
A 
5’ GAC CGC ACC AAC AGT GTG AA 
5’ TGG TTG CTG AGG CAG AAG GT 
231 
Tenomodulin  
(Tnmd) 
S 
A 
5’ CCC GTG ACC AGA ACT GAA AT 
5’ GTT GCA AGG CAT GAT GAC AC 
232 
Osterix  
(Osx) 
S 
A 
5’ GGC TAT GCC AAT GAC TAC CC 
5’ GGT GAG ATG CCT GCA TGG AA 
207 
Runx2 S 
A 
5’ CAG ACC AGC AGC ACT CCA TA 
5’ CAG CGT CAA CAC CAT CAT TC 
177 
Osteonectin 
(Osn) 
S 
A 
5’ AAC CTT CTG ACC GAG AAG CA 
5’ TGG GAC AGG TAC CCA TCA AT 
190 
ALP S 
A 
5’ TGG GGT GAA GGC TAA TGA GG 
5’ GGC ATC TCG TTG TCC GAG TA 
221 
PPAR S 
A 
5’ TGC TGT GGG GAT GTC TCA TA 
5’ GGT CAG TGG GAA GGA CTT GA 
212 
Adiponectin 
(Adpn) 
S 
A 
5’ AGG ACA AGG CTG TGC TCT TC 
5’ GAA GGA AGC CTG TGA AGG TG 
202 
FABP4  S 
A 
5’ AGG ACA AGG CTG TGC TCT TC 
5’ GAA GGA AGC CTG TGA AGG TG 
202 
Sox9 S 
A 
5’ GAA CGC ACA TCA AGA CGG AG 
5’ CTG GTG GTC TGT GTA GTC GT 
304 
Col II S 
A 
5’ AGC AGG AAT TTG GTG TGG AC 
5’ TCT GCC CAG TTC AGG TCT CT 
223 
Aggrecan 
(Agg’n) 
S 
A 
5’ GAC GCC GAG AGC AGG TGT 
5’ AAG AAG TTG TCG GGC TGG TT 
202 
EF1-alpha S 
A 
5’ CCC GGA CAC AGA GAC TTC AT 
5’ AGC ATG TTG TCA CCA TTC CA 
328 
 
 
 
Table 3.1: Primers used for real-time PCR amplification. 
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Figure 3.1: (A) Population doubling time and (B) population doublings of TDPC fractions, 
during the first (P1) and second (P2) passages of monolayer expansion (mean + SE; n = 4).  
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Figure 3.2: Immunophenotypic profile of third passage TDPC fractions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Relative mRNA expression of tenogenic genes, scleraxis (Scx) and tenomodulin 
(Tnmd) in TDPC fractions (mean + SE; n = 4).  
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Figure 3.4: (A) Alizarin Red staining (X 10 magnification) of day 0, 7 and 14 osteogenic 
cultures. TPP0 (upper panels), TPP3 (middle panels), TPP7 (lower panels). Scale = 100 microns.  
(B) Relative mRNA expression of osteogenic genes; osterix (Osx), Runx2, osteonectin (Osn) and 
alkaline phosphatase (ALP) in day 14 TDPC cultures (mean + SE; n = 4). 
A 
B 
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Figure 3.5: (A) Oil-Red-O staining (X 50 magnification) of day 0, 3 and 10 adipogenic cultures. 
TPP0 (upper panels) , TPP3 (middle panels), TPP7 (lower panels). Scale = 100 microns.  
(B) Relative mRNA expression of adipogenic genes; PPARγ, adiponectin (ADPN) and fatty acid 
binding protein-4 (FABP4) in day 10 TDPC cultures (mean + SE; n = 4). 
A 
B 
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Figure 3.6: (A) Toluidine blue staining (X 10 magnification) of day 20 chondrogenic pellets. 
Scale = 100 microns. (B) Relative mRNA expression of chondrogenic genes; Sox9, aggrecan 
(Agg’n) and collagen type II (Col II) in day 20 chondrogenic pellets (mean + SE; n = 4).  
 
 
 
 
A 
B 
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CHAPTER 4: COMPARISON OF EQUINE TENDON- AND BONE MARROW– 
DERIVED CELLS CULTURED ON TENDON MATRIX WITH OR WITHOUT 
INSULIN-LIKE GROWTH FACTOR-I SUPPLEMENTATION 
This chapter was published as an original research article in the American Journal of Veterinary 
Research in 2012.c  
 
Introduction:  
Tendinitis is a common cause of breakdown injury in equine athletes and accounts for 30% to 
50% of all racing injuries [1-3]. Tendon injuries are often degenerative injuries, and the 
prevalence of tendinitis increases with age [3]. Despite improvements in early detection and 
monitoring, the tissue that is deposited during the process of tendon repair does not restore the 
original matrix organization and biomechanical properties [4-8]. As a consequence, reinjury is 
common (up to 43% of tendon strain injuries) [1]. 
          
Mesenchymal stem cells are characterized by their ability to maintain considerable proliferative 
activity and differentiate along several tissue lineages (ie, multipotency). These characteristics 
have generated research interest for use in addressing the potential of MSCs in tissue 
regeneration [9-13]. Most of these studies [11,12,14] have focused on MSCs derived from bone 
marrow aspirates. Both bone marrow– and adipose-derived cells have been used empirically for 
the treatment of tendonitis in horses. Only few controlled studies [15-19] have been reported.  
 
c Durgam, S.S., Stewart, A.A., Pondenis, H.C., et al. 2012. Comparison of equine tendon- and bone marrow-derived 
cells cultured on tendon matrix with or without insulin-like growth factor-I supplementation. American Journal of 
Veterinary Research, 73, pp. 153-161. 
 
 
60 
It has been indicated in several studies [19-22] that alternative sources of progenitor cells might 
also be beneficial for specific therapeutic applications, which include treatment of tendon 
injuries. In another study [22] conducted by our research group, it was found that tendon- and 
muscle-derived cells proliferated more rapidly in vitro and had better viability and greater 
tenogenic matrix production, compared with results for bone marrow–derived cells. 
          
Tendons are composed of longitudinally oriented fibrillar collagen, predominantly collagen type 
I, that accounts for 75% of the tissue [8,23]. Tendons also contain collagen type III, which 
comprises approximately 14% of total collagen in physiologically normal tendons [24]. The 
COMP is a glycoprotein secreted by tenocytes that helps regulate the diameter of collagen fibrils 
[25]. Synthesis of both collagen and proteoglycan are increased in healing tendons [29,30]. 
Specifically, collagen type III and COMP concentrations are increased in the acute stage of 
healing, and both participate in collagen type I fibrillogenesis [25-29]. Independent of the matrix 
synthesis responses, restoration of the normal architecture of the ECM is critical to effective 
tendon repair because a high degree of alignment of collagen fibrils is critical for the ability of 
flexor tendons to withstand high recurrent tensile loads. 
             
In vitro and in vivo studies [31-34], investigators have reported benefits for the administration of 
growth factor to tenocytes. Exogenous injections and transfection of bone marrow–derived 
MSCs with IGF-I stimulated tendon healing in horses with tendinitis experimentally induced by 
the injection of collagenase [15,34]. In several studies [31-34], IGF-I stimulated matrix synthesis 
and ECM production in tendons and ligaments. In early stages of tendon repair, IGF-I protein 
concentrations decrease by 40%, compared with protein concentrations in physiologically 
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normal tendon; however, by 4 weeks after injury, tissue concentrations of IGF-I peak, although 
they remain elevated through 8 weeks after injury [30]. Therefore, supplementation with 
exogenous IGF-I during the early phases of tendon repair may provide a therapeutic advantage 
[15,30,33,34]. The plasma concentration of IGF-I ranges from 25 to 82 ng/mL in clinically 
normal horses [35]. In the study reported here, we used an IGF-I concentration of 100 ng/mL, 
which was selected on the basis of the results of an in vitro flexor tendon explant study [33] 
conducted by other investigators and a stem cell study conducted by our research group. This 
IGF-I concentration significantly increases in vitro cell number and matrix synthesis [31,33]. 
         
The objective of the study reported here was to compare in vitro growth characteristics of 
tendon- and bone marrow–derived cells during monolayer expansion. We also assessed matrix 
production and matrix gene expression of monolayer-expanded cells cultured on acellular tendon 
matrix. The effects of IGF-I supplementation on gene expression and matrix production were 
assessed in both cell populations. The hypothesis tested was that tendon-derived cells 
supplemented with IGF-I would grow and persist on matrix better and produce more tendon 
ECM than would cells derived from bone marrow. 
 
Materials and Methods: 
Samples: Samples of bone marrow and tendon were collected aseptically from 7 young horses (2 
to 4 years of age) euthanized for reasons unrelated to musculoskeletal disease. Horses were 
sedated with xylazine hydrochloride (0.5 to 1.0 mg /kg, IV), and anesthesia was induced by IV 
administration of ketamine hydrochloride (2.2 mg/kg) and diazepam (0.1 mg/kg). Anesthesia 
was maintained by IV infusion of a solution of 5% guaifenesin, 1 mg of ketamine/mL, and 1 mg 
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of xylazine/mL. Bone marrow aspirates were collected as described elsewhere [36]. Then, all 
horses were euthanized by IV administration of sodium pentobarbital (104 mg/kg, IV). 
Immediately after the horses were euthanized, both superficial digital flexor tendons were 
harvested aseptically from each horse. All samples were obtained in accordance with guidelines 
reviewed and approved by the Institutional Animal Care and Use Committee of the University of 
Illinois. 
 
Collection and processing of bone marrow–derived cells: The right tuber coxae was clipped 
of hair and aseptically prepared. A bone marrow biopsy needle was used to aspirate 15 to 20 mL 
of bone marrow into syringes that contained 1,000 U of heparin. The bone marrow aspirate was 
transferred to a centrifuge tube, diluted with 15 mL of PBS solution, and centrifuged at 300 X g 
for 10 minutes. Supernatant was removed, the pellet was resuspended in PBS solution, and 
centrifugation was repeated. Pelleted cells were resuspended in 12 mL of low-glucose DMEM 
supplemented with 10% FBS, 300 µg of L-glutamine/mL, 100 U of sodium penicillin/mL, 100 
µg of streptomycin sulfate/mL, and 1mM sodium pyruvate/mL. Resuspended cells were placed 
in a 75-cm2 flask and incubated at 37oC in a 5% carbon dioxide atmosphere with 90% humidity. 
To obtain adequate cell numbers for subsequent experiments, bone marrow–derived cells were 
passaged twice. Time to confluence and cell counts at time of trypsinization were recorded for all 
cell types at each passage. 
 
Collection and processing of tendon-derived cells: A 6-cm X 1-cm2 sample of each superficial 
digital flexor tendon was reserved for cell isolation. A 2-cm3 sample was snap-frozen in liquid 
nitrogen for RNA isolation, and the remainder was cryopreserved for cell-free tendon matrix 
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production. The specimen for cell isolation was diced into small pieces and digested for 16 hours 
at 37oC in 0.2% collagenase-high-glucose DMEM supplemented with 1% FBS, 100 U of sodium 
penicillin/mL, and 100 µg of streptomycin sulfate/mL. After digestion, the isolated cells were 
passed through a 40-µm filter. The isolated cells were collected by centrifugation at 300 X g for 
5 minutes. Supernatant was removed, and the cell pellet was resuspended in culture medium 
containing high-glucose DMEM supplemented with 20% FBS, 300 mg of L-glutamine/mL, 100 
U of sodium penicillin/mL, and 100 µg of streptomycin sulfate/mL. Cell yields were determined 
by use of a hemacytometer, and viability was determined via trypan blue dye exclusion [37]. 
 
Culture of tendon-derived cells: Progenitor cells were collected from tendon samples by use of 
previously described preplating procedures [23,32]. Tendon-derived cells were seeded at 13,300 
cells/cm2 in culture flasks in high-glucose DMEM supplemented with 20% FBS, 300 mg of L-
glutamine/mL, 100 U of sodium penicillin/mL, and 100 µg of streptomycin sulfate/mL. Rapidly 
adherent fibroblast-like cells were excluded by differential attachment whereby the culture 
medium and unattached cells were serially transferred to fresh culture flasks every 24 hours 
during the first 72 hours of culture [22,38]. Tendon-derived cells that adhered after the transfer at 
72 hours were expanded in monolayer for subsequent experiments. 
 
Tendon matrix culture: Samples of superficial digital flexor tendons were cut longitudinally 
with a dermatome to produce uniformly flat 0.5-mm-thick tendon sheets. These sheets were cut 
into 1 X 1-cm square explants. The explants were subjected to 4 rounds of freeze-thaw cycles at 
–80o and 4oC to kill endogenous cells. These cell-free tendon explants (matrix only) were 
 
64 
maintained in culture without the addition of cells to serve as negative control samples or seeded 
with aliquots (125,000 cells) of the monolayer-expanded bone marrow– or tendon-derived cells.  
            
Experiments comprised 5 treatment groups (matrix only, matrix and bone marrow–derived cells, 
matrix and bone marrow–derived cells with IGF-I, matrix and tendon-derived cells, and matrix 
and tendon-derived cells with IGF-I). Each treatment group had 14 replicates. The 14 replicates 
were distributed into 3 samples for cell numbers, 3 samples for collagen synthesis, 5 samples for 
GAG synthesis, and 2 samples for histologic evaluation. The mean of all replicates was 
calculated to yield a single data point for each horse. Total RNA was isolated from 3 of the 7 
horses. Treatment groups established for RNA isolation had an additional 12 replicates. There 
were 70 to 130 samples for each of the 7 horses. 
           
Cell-seeded tendon matrices were supplemented with 1 mL of tenogenic media that contained 0 
or 100 ng of IGF-I. Tenogenic media consisted of high-glucose DMEM supplemented with 10% 
FBS, 37.5 µg of ascorbic acid/mL, 300 µg of L-glutamine/mL, 100 U of sodium penicillin/mL, 
and 100 µg of streptomycin sulfate/mL. Media were changed every 2 days. All culture samples 
were collected on day 7 (day 0 was the first day of cell culture). 
 
Cell numbers on matrices: Three cell matrices from each treatment group were used to measure 
cell number on day 7 via a mitochondrial metabolic assay, which was used in accordance with 
the manufacturer’s instructions. In brief, 50 µL of the assay reagent containing tetrazolium was 
added to fresh media in each well, and wells were incubated at 37oC for 2.5 hours. One hundred 
microliters of media from each well was transferred to a 96-well plate, and absorbance was 
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measured at 492 nm in a microplate reader to detect concentrations of the metabolic product, 
formazan. All samples were assayed in duplicate, and a mean value was calculated to provide a 
single data point. These optical density values were converted to cell numbers by reference to 
standard curves determined from plated tendon- and bone marrow–derived cells from each horse. 
 
Collagen synthesis: Collagen synthesis was determined by measuring [3H] prolineo 
incorporation by use of a published protocol [39]. On day 6, 3 cell matrices of each treatment 
group were radiolabeled with 50 µCi of [3H] proline/mL of tenogenic medium and incubated for 
24 hours. The samples were washed 3 times with 0.5 mL of PBS solution containing 1mM 
proline and stored at –80oC. Radiolabeled samples were freeze-thawed 3 times, digested, and 
homogenized to disrupt cells and matrix prior to RNase treatment. Total protein was precipitated 
with tricholoroacetic acid and washed 3 times with L-proline to remove traces of unincorporated 
[3H] proline. The resulting pellets were digested with purified collagenase, and centrifuged at 
3,220 X g for 10 minutes. Supernatant and the pelleted material were separated and added to 
scintillation liquid, and radioactivity was counted by use of a scintillation counter. Newly 
synthesized collagen was detected on the basis of radioactivity in the sample supernatants 
following collagenase digestion [39]. Collagen synthesis was normalized for background 
amounts by subtracting the number of disintegrations per minute of the explant-only control 
samples. Values were expressed as the number of disintegrations per minute per explant seeded 
with 125,000 cells. 
 
GAG synthesis: Synthesis of GAG was determined by measuring 35SO4 incorporation into each 
sample. Five cell matrices of each treatment group were radiolabeled with 10 µCi of 35S-labeled 
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sodium sulfate/mL during the last 24 hours of the experiment. Samples were washed 3 times with 
PBS solution and then digested in 1 mL of buffer that contained 0.5 mg of papain at 65oC for 16 
hours [40]. Aliquots (25 mL) of 35S-labeled papain-digested tendon matrices were placed in 
multiwell punch plates, precipitated with alcian blue dye, and counted by use of scintillation. All 
CPM values were adjusted for radioisotope decay from the time of radiolabeling to assay. 
Proteoglycan synthesis was normalized for background amounts by subtracting the CPM of the 
explant-only control samples. Values were expressed as the number of CPM per explant seeded 
with 125,000 cells. 
 
RNA isolation: Sufficient numbers of cells were generated from 3 horses to support 
transcriptional analyses. Twelve cell matrices from each treatment group were pooled, snap-
frozen in liquid nitrogen, and stored at –80oC for RNA isolation. The RNA was isolated by use 
of a protocol adapted from a technique for cartilage RNA isolation [41]. Briefly, tissues were 
pulverized under liquid nitrogen, homogenized in guanidinium isothiocyanate lysis buffer, 
extracted with phenol-chloroform, precipitated with isopropanol, and purified by use of a 
commercially available column-based procedure. This procedure included an on-column DNase 
treatment to exclude contamination of the genomic template. 
 
Real-time PCR gene expression: One microgram of RNA from each sample was converted to 
cDNA by use of a commercial reverse transcription kit and oligo(dT) primers. Target cDNAs 
were amplified via real-time PCR assay by use of Taq DNA polymerase and gene-specific 
primers designed by use of a multiple sequence alignment program from published sequences 
available in GenBank. Primer specificity was confirmed by cloning and sequencing the PCR 
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products. Real-time quantitative PCR was performed in triplicate for the equine specific primers 
collagen type I, collagen type III, and COMP mRNAs and the reference gene, elongation factor-
1α. The generated amplicons were quantified by incorporation of a fluorescent dye by use of a 
commercial fluorescent PCR detection system. To relate in vitro expression to in vivo 
expression, RNA from freshly collected, snap-frozen tendon samples was used as a reference for 
gene expression analyses. Relative gene expression was quantified by use of the 2–ΔΔCT method 
[42]. 
 
Gene expression on northern blots: Northern blot analyses of collagen type I, collagen type III, 
and COMP mRNAs were performed on samples obtained from 1 horse. Gel electrophoresis and 
northern blot analyses of RNA samples were performed in accordance with standard protocols 
[43]. Radiolabeled probes were synthesized from gel-purified partial cDNA templates by use of 
32P-dCTP and random 9-mer primers and were purified through spin columns. Consistency of 
RNA sample loading was assessed via electrophoresis followed by ethidium bromide staining of 
the gels. The RNAs were transferred to nylon hybridization membranes via capillary transfer by 
use of a high-salt buffer, as described elsewhere [43]. Elongation factor-1α was used for 
normalization of gene expression. Prehybridization, hybridization, and wash conditions were as 
described in protocols recommended by the manufacturer of the nylon membranes. Northern blot 
data were quantified by use of a computer workstation and commercially available software. 
 
Histologic examination: Two tendon samples from each treatment group were fixed in 4% 
paraformaldehyde and embedded in paraffin in accordance with routine protocols. Sections 
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(thickness of 6 µm) were stained with H&E for evaluation of the cell layers colonizing the 
matrix surfaces. 
 
Statistical analysis: Mean ± SE value for each variable was calculated for each cell type and 
IGF-I supplementation status for tendon samples obtained from each of the 7 horses in the study. 
Background values detected in the matrix-only group were subtracted from values for the other 
groups. Data for cell number, GAG synthesis, and collagen synthesis were logarithmically 
transformed to accommodate between-horse variability. In addition, collagen type I, collagen 
type III, and COMP mRNA expression were normalized to expression of the reference gene, 
elongation factor-1α. The effects of cell type and IGF-I supplementation were evaluated by use 
of generalized estimating equations, which is a method robust to violation of assumptions 
required for a repeated-measures ANOVA [44]. When group differences were detected, pairwise 
multiple comparisons were conducted by use of nonparametric tests. A statistical program was 
used to perform statistical analyses. Values of P ≤ 0.05 were considered significant. Mean ± SE 
values were determined for days to confluence and cell number following monolayer expansion 
of bone marrow– and tendon-derived cells. 
 
Results: 
Cell isolation and expansion: After the completion of preplating procedures and cell 
attachment, the cells from bone marrow and tendon proliferated in focal clones of tightly packed 
cells with fusiform morphologic characteristics. During the first passage, bone marrow–derived 
cells reached focal confluence significantly (p = 0.006) more rapidly than did tendon-derived 
cells (Table 4.1). However, during the second passage, tendon-derived cells reached confluence 
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significantly (p = 0.018) more rapidly than did bone marrow–derived cells. After 2 passages, 
there was no significant (p = 0.12) difference for the number of days to confluence between bone 
marrow– and tendon-derived cells. Both cell types required 17 to 19 days to complete 2 
passages. Cell numbers at the first and second passage were significantly (p = 0.01 and 0.004, 
respectively) higher for tendon-derived cells than for bone marrow–derived cells. Tendon-
derived cell expansion yielded significantly (p = 0.004) more cells (mean of approximately 6.7 X 
106 more cells), compared with the number of cells in bone marrow–derived cell cultures. 
 
Cell numbers on matrices: After culture for 7 days, the mean log10 numbers of cells adherent to 
the acellular tendon matrices were significantly (p < 0.001) increased in the tendon-derived cell 
groups, compared with the numbers in the bone marrow–derived cell groups (Figure 4.1). In 
addition, cell numbers in the IGF-I–treated groups were significantly (p = 0.002) increased, 
compared with the cell numbers in cell groups cultured without IGF-I. Evaluation of cell 
numbers for the cell-free matrix-only group revealed that there were no viable cells in these 
control cultures. Results of statistical analysis for transformed and untransformed data were 
summarized (Table 4.2). 
 
Collagen synthesis: Mean log10 collagen synthesis was significantly (p < 0.001) increased in the 
tendon-derived cell groups, compared with synthesis in the bone marrow–derived cell groups 
(Figure 4.2). Treatment with IGF-I significantly (p = 0.01) increased the mean log10 collagen 
synthesis of tendon-derived cells. There was no significant effect of IGF-I supplementation on 
collagen synthesis by bone marrow–derived cells. Results of statistical analysis for transformed 
and untransformed data were summarized (Table 4.2). 
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GAG synthesis: Mean log10 GAG synthesis was significantly (p = 0.001) increased in the 
tendon-derived cell groups, compared with GAG synthesis in the bone marrow–derived cell 
groups (Figure 4.3). Treatment with IGF-I significantly (p < 0.001) increased the mean log10 
GAG synthesis in both the tendon- and bone marrow–derived cell groups. Results of statistical 
analysis for transformed and untransformed data were summarized (Table 4.2). 
 
mRNA expression in the ECM: No mRNA was isolated from the acellular control tendon 
matrices that were subjected to 4 freeze-thaw cycles. Sufficient quantities of RNA for further 
analyses were obtained from only 3 of 7 horses in the study because of inherent difficulty in 
isolating RNA from a relatively small number of viable cells within a large volume of dense, 
acellular matrix. Quantitative PCR analyses of collagen type I mRNA expression in the cell-
matrix groups revealed no significant differences between bone marrow– and tendon-derived cell 
groups (p = 0.08) or in response to IGF-I administration (p = 0.08; Table 4.3). Similarly, there 
was no significant difference in collagen type III expression between tendon-derived cell groups 
(p = 0.95) or in response to IGF-I (p = 0.32). Although tendon-derived cells expressed 3- to 5-
fold more COMP mRNA than did bone marrow–derived cells, the expressions did not differ 
significant (p = 0.16). Supplementation with IGF-I did not significantly (p = 0.80) affect COMP 
mRNA expression. 
 
Northern blot analyses of collagen types I and II and COMP mRNAs from total RNA isolated 
from cells collected from 1 horse had expression profiles that were consistent with the real-time 
PCR results (Table 4.4). 
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Histologic examination: In all cell-treated groups, the cells were predominantly adherent to the 
surface of the autogenous matrices (Figure 4.4). Tendon-derived cells were present in higher 
numbers than were bone marrow–derived cells, and IGF-I treatment increased matrix-associated 
cell numbers in both cell types, which was consistent with the cell count data. In addition, 
tendon-derived cells appeared to have a more elongate tenocyte-like appearance, compared with 
the appearance of the bone marrow–derived cells. 
 
Discussion: 
In the study reported here, initial yields of tendon-derived cells were significantly higher than 
were yields from bone marrow aspirates, and tendon-derived cells were easier to culture during 
first passage. Tendon- and bone marrow–derived cell cultures both required approximately 17 to 
19 days to reach second passage confluence. However, after 2 passages, sufficient numbers of 
tendon-derived cells were generated for most cell-based treatments that have been used  
in the treatment of tendinitis [15,19]. These results are similar to those of another study [22] in 
which more cells were obtained at confluence from tendon-derived cell cultures than from bone 
marrow–derived cell cultures. It is possible that bone marrow–derived cells could have provided 
higher cell yields with different isolation techniques, such as density gradient centrifugation and 
initial RBC lysis [45,46]. Although greater numbers of tendon-derived cells can be obtained in a 
shorter period, donor site morbidity remains a concern. These concerns were addressed in a 
recent study in which our research group evaluated tendon-derived cells obtained from the lateral 
digital extensor tendon as a clinically relevant sample. To our knowledge, there have been no 
adverse effects of collecting tissue from the lateral digital extensor tendon for at least 4 months 
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after tenectomy. Longer follow-up evaluation of the lateral digital extensor tenectomy site in 
clinically normal horses is warranted prior to use in clinically affected horses. 
 
In the present study, tendon-derived cells persisted on the acellular matrix and continued to 
proliferate during the 7-day culture period. In contrast, bone marrow–derived cell numbers did 
not change from the original seeding density. Supplementation with IGF-I increased (2-fold 
increase) tendon- and bone marrow–derived cell numbers, compared with cell numbers for 
unsupplemented cultures. The IGF-I–mediated increase in cell numbers could have resulted from 
an increase in in cell survival rate or cell proliferation. Investigators in several other in vitro 
studies [31-33] have detected similar increases in tenocyte cell numbers with IGF-I 
supplementation. In a recent study [47] it was found that IGF-I supplementation increases cell 
numbers by reversing cell cycle arrest, which suggests that cell proliferation was a factor in the 
increase in cell numbers in the study reported here. 
         
Considerable increases in collagen and GAG synthesis were detected in tendon-derived cells, 
compared with results for bone marrow–derived cells, which was consistent with results of 
another study [22]. Supplementation with IGF-I further increased matrix synthesis by tendon-
derived cells, compared with synthesis in unsupplemented control samples. These results are 
similar to those of several in vivo and in vitro studies [15,31-33] in which investigators detected 
IGF-I enhancement of tendon matrix synthesis. Some of these in vitro anabolic effects of IGF-I 
are mediated through increases in mitogenesis, with consequent increases in population-wide 
matrix synthesis. However, it should be mentioned that the matrix synthesis results in the present 
study were expressed in terms of cell numbers at the start of the experiments and did not account 
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for possible changes in cell numbers as a consequence of differential persistence or proliferation 
during the course of the experiments. Further evaluation is required before specific conclusions 
can be drawn regarding the biosynthetic capacities of these cell types and their responses to IGF-
I supplementation. 
 
In the present study, there were no significant differences in expression of collagen type I, 
collagen type III, and COMP mRNAs by cell type or in response to IGF-I supplementation. 
However, values of P > 0.05 but < 0.10 were obtained for collagen type I (with and without IGF-
I supplementation) and collagen type III (without IGF-I supplementation). The mRNA data in 
the present study were derived from samples of only 3 horses, and this may have been an 
insufficient sample size to adequately assess differences in mRNA concentrations because of low 
statistical power. In addition, results from another study [22] conducted by our research group 
revealed significantly greater collagen type III expression by tendon-derived cells than by bone 
marrow–derived cells (data derived from samples of 4 horses). In that study [22], there was no 
difference in collagen type I or COMP mRNA expression in these cell types. Furthermore, the 
results of the present study are similar to those of other studies [33,48] in which IGF-I 
supplementation had minimal effects on ECM gene expression despite overall increases in 
tendon matrix synthesis. Regardless, increases in matrix synthesis per explant are a more 
important outcome variable than are changes in mRNA expression. 
           
Results from the present study support the hypothesis that tendon-derived cells supplemented 
with IGF-I grow and adhere to acellular matrix better and produce more ECM than do cells 
derived from bone marrow. These results suggest that tendon-derived cells may be a better 
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source for cells used in repair of tendon injuries. Supplementation with IGF-I enhances cell 
persistence and proliferation and matrix synthesis. Results of this study support further in vivo 
evaluation of tendon-derived cells and IGF-I for use in tendon repair. 
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Tables and Figures:  
 
 
 
 
 
 
 
Table 4.1—Mean ± SE values for number of days to passage 1 and 2 and number of cells at the 
time of passage during monolayer culture of bone marrow– and tendon-derived cells. 
 
Values represent results for samples obtained from 7 horses.  
*Value differs significantly (P ≤ 0.05) from the value for bone marrow–derived cells. 
 
 
 
 
Table 4.2—Mean ± SE values for number of cells, collagen synthesis, and GAG synthesis for 
equine bone marrow– and tendon-derived cells cultured with and without IGF-I on a tendon 
matrix for 7 days. 
 
Values represent results for samples obtained from 7 horses. 
*Within a row, value differs significantly (P ≤ 0.05) from the value without IGF-I. †Within a row, value differs 
significantly (P ≤ 0.05) from the corresponding value for bone marrow–derived cells. 
DPM = Disintegrations per minute. 
Variable Bone marrow Tendon 
No. of days to passage 1 12.8 ± 0.5 17.3 ± 0.3* 
No. of days to passage 2 4.5 ± 1.0 2.3 ± 0.3* 
Total No. of days to passage 2 17.3 ± 0.9 19.5 ± 0.5 
No. of cells at passage 1 (X 106) 0.28 ± 0.75  1.18 ± 0.22* 
No. of cells at passage 2 (X 106) 0.94 ± 0.06  6.30 ± 0.99* 
Total No. of cells for passage 1 and 2 (X 106) 1.21 ± 0.11  7.95 ± 0.86* 
Variable Bone  
Without IGF-I 
marrow  
With IGF-1 
Tendon 
Without IGF-1 
  
With IGF-I 
No. of cells/explant 85,649 ± 43,619 190,924 ± 
87,173 
215,430 ± 
100,923 
472,970 ± 
105,612 
Log10 No. of 
cells/explant 
4.81 ± 2.60 8.21 ± 2.36*  10.03 ± 1.85† 12.93 ± 
0.21*† 
 
Collagen synthesis  
(DPM/ explant) 
52,361 ± 21,870 42,545 ± 
11,574 
61,418 ± 11,956 99,987 ± 
20,172 
Log10 collagen 
synthesis  
(Log10 
DPM/explant) 
10.37 ± 0.52 10.40 ± 0.37  10.87 ± 0.29† 11.29 ± 
0.37*† 
GAG synthesis  
(CPM/explant) 
6,232 ± 1,574  12,776 ± 
5,191 
25,605 ± 8,764 49,133 ± 
16,520  
Log10 GAG 
synthesis  
(Log10 CPM/explant) 
8.41 ± 0.39 8.98 ± 0.42* 9.86 ± 0.30† 10.53 ± 
0.30*† 
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Table 4.3—Results for real-time PCR evaluation of mRNA expression of bone marrow– and 
tendon-derived cells after culture with and without IGF-I on a tendon matrix for 7 days.  
 
Values reported are mean ± SE; values for mRNA expression of collagen type I, collagen type III, and COMP were 
normalized on the basis of expression for elongation factor-1α. Values represent results for samples obtained from 3 
horses. A physiologically normal tendon was used as a positive control sample. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.4—Results for northern blot evaluation of mRNA expression for bone marrow– and 
tendon-derived cells after culture with and without IGF-I on a tendon matrix for 7 days.  
 
Values reported are the mean mRNA expression of collagen type I, collagen type III, and COMP after normalization 
on the basis of expression for elongation factor-1α. Values represent results for samples obtained from 3 horses. 
*Physiologically normal tendon (positive control sample). 
 
 
 
 
 
 
 
 
Variable Tendon 
Without IGF-I 
 
With IGF-I 
Bone  
Without IGF-I 
marrow  
With IGF-I 
Collagen type I 1.00 ± 0 1.76 ± 0.22 2.12 ± 0.36 2.09 ± 0.56 
Collagen type III 1.00 ± 0 1.27 ± 0.62 0.96 ± 0.54  1.07 ± 0.48 
COMP 1.00 ± 0 1.15 ± 0.50 0.373 ± 0.28 0.213 ± 0.10 
Variable Control 
tendon*  
Tendon 
Without 
IGF-I 
 
With 
IGF-I 
Bone marrow 
Without IGF-I 
  
With IGF-I 
Collagen type I 1.06 1.64 1.57 1.49 2.11 
Collagen type III 0.39 3.66 4.32 4.32 3.54 
COMP 0.81 0.83 0.70 0.82 0.89 
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Figure 4.1—Log10 mean ± SE cell numbers for tendon- and bone marrow–derived cells cultured 
on tendon matrix for 7 days with IGF-I (100 ng/mL [white bars]) or without IGF-I (gray bars). 
Values represent results for samples obtained from 7 horses. 
 
 *Value differs significantly (P ≤ 0.05) from the corresponding value for the bone-marrow–derived cells. †Within a 
cell type, value differs significantly (P ≤ 0.05) from the value for cells cultured without IGF-I.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2—Log10 mean ± SE disintegrations per minute (DPM) as a measure of incorporation 
of [3H] proline into collagen of the tendon matrix after seeding with tendon- and bone marrow–
derived cells and culture for 7 days.  
 
Values represent results for samples obtained from 7 horses. 
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See Figure 4.1 for key.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3—Log10 mean ± SE CPM as a measure of incorporation of 35S-labeled sodium sulfate 
into GAG of the tendon matrix after seeding with tendon- and bone marrow–derived cells and 
culture for 7 days.  
 
Values represent results for samples obtained from 7 horses. 
See Figure 1 for key. 
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Figure 4.4—Photomicrographs of sections of tendon matrix seeded with equine bone marrow–
derived cells and cultured with (A) and without (B) IGF-I for 7 days or with tendon-derived cells 
and cultured with (C) and without (D) IGF-1 for 7 days. All cells are adhered to the surface of 
the acellular matrix. Subjectively, tendon-derived cells had a higher number of cells arranged in 
a linear fashion, compared with results for bone marrow–derived cells. Tendon-derived cells 
cultured with IGF-I had the highest number of cells, compared with results for the other 
treatment groups. H&E stain. Bar = 50 µm. 
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CHAPTER 5: TENDON-DERIVED PROGENITOR CELLS IMPROVE HEALING OF 
COLLAGENASE-INDUCED FLEXOR TENDINITIS 
This chapter was recently accepted for publication as an original research article in the Journal of 
Orthopaedic Research, doi: 10.1002/jor.23251, [Epub ahead of print].d  
 
Introduction 
         Tendinitis/tendinopathy is a common and debilitating injury in athletes, manifesting acutely 
or as chronic strain type injury. Achilles tendons in humans and superficial digital flexor (SDF) 
tendons in horses are functionally analogous and have a high-energy storing capacity in tension. 
At high speeds, these tendons function close to their maximal capacity and are, therefore, prone 
to strain injury [1]. SDF tendon injuries in equine athletes are a common cause of lameness with 
incidence rates of 11-30% [2]. Similarly, up to 75% of Achilles injuries in humans are related to 
athletic activities [3,4]. Tendons in general have a poor healing capacity, and require prolonged 
rehabilitation after treatment of the acute injury.5 Regardless, the resultant repair tissue is 
biomechanically inferior to the original tendon, and therefore recurrence rates can be as high as 
30% [1,4,5]. This has stimulated a number of studies focused on cell-based and/or biologic 
therapies to improve tendon healing.  
          Although progenitor cells share common characteristics of clonogenecity, multipotentiality 
and self-renewal, they also retain source-specific characteristics which likely influence their 
responses in target tissues [6,7]. Intuitively, progenitor cells derived from the ‘low-cell, collagen- 
 
d Durgam, S.S, Stewart, A.A., Wagoner-Johnson, A.J., Sivaguru, M., Stewart, M.C. Tendon-derived progenitor cells 
improve healing of collagenase-induced flexor tendinitis. Journal of Orthopaedic Research, doi: 10.1002/jor.23251 
[EPub ahead of print]. 
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rich’ environment of tendons may be more efficacious for treating tendinitis than other cell 
populations [8]. Tendon-derived progenitor cells (TDPCs) have been characterized in humans8 
and rodents [8,9]. Allogeneic TDPC administration in rodent models of tendon injury improved 
histologic and biomechanical indices of repair [10,11]. In vitro, equine TDPCs exhibited greater 
colonization, proliferation and matrix synthesis than bone marrow-derived mesenchymal stem 
cells (BM-MSCs) when cultured on acellular tendon matrices [12]. The objective of this study 
was to evaluate the efficacy of autogenous TDPC injections in a large animal model of flexor 
tendinitis using transcriptional, biochemical, histological and biomechanical outcomes.  
 
Methods: 
Study Design: All procedures were approved by the University of Illinois Institutional Animal 
Care and Use Committee. Eight young adult horses (2-4 years of age) free of musculoskeletal 
disease were used for this 16-week study. On the first day of the study, both forelimb SDF 
tendons were injected with collagenase, as detailed below. Four weeks later, one randomly 
assigned forelimb SDF tendon was injected with TDPCs, and the contralateral SDF tendon was 
injected with saline. In each horse, a randomly selected hindlimb SDF tendon was used to 
monitor the survival and distribution of TDPCs, 1, 2, 4 and 6 weeks after administration (2 
horses at each time point; Figure 5.1). The remaining untreated hindlimb SDF tendon in each 
horse was used as a within-animal ‘normal’ control. The study was terminated after 16 weeks; 
corresponding to 12 weeks after the forelimb TDPC/saline injections. 
 
Collagenase Model: Both forelimb SDF tendons were injected with sterile collagenase 
(Worthington Biochemical Corporation, Lakewood, NJ). One thousand units of collagenase were 
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injected at 2 sites, 3 cm proximal and 3 cm distal to the center of the metacarpal region, with 
ultrasonographic guidance, as previously described [13-15]. Within 24 hours of collagenase 
injections, there was marked swelling of the SDF tendon, and the tendons were painful on 
palpation. Horses were lame at a walk for the first post-injection week; however, the lameness 
and local signs of pain responded favorably to systemic anti-inflammatories and was resolved by 
the second week. All horses’ distal limbs were bandaged and the horses were stall-rested for the 
subsequent two months.  
        
Collagenase lesions were also created in a randomly selected hindlimb SDF tendon of each horse 
at 5, 6, 8 and 10 weeks before the termination of the study (two horses at each time point). These 
time points were chosen to assess survival and distribution of TDPCs at the site 1, 2, 4 and 6 
weeks after injection.  
 
TDPC Isolation and Culture: At the time of forelimb collagenase injections, lateral digital 
extensor (LDE) tendon was harvested from one of the hindlimbs, under regional analgesia.16 A 
4-cm linear skin incision was made on the lateral surface of the proximal metatarsus starting at 
the distal insertion of the LDE tendon and extended proximally. A 0.5 x 1.0 cm2 section of LDE 
tendon was collected and diced into 0.25-cm3 and digested in 0.2% collagenase in DMEM 
supplemented with 2% fetal bovine serum at 37oC for 16 hours [16]. The cells were isolated by 
filtration and centrifugation and the cells were seeded at 10,000 cells/cm2 in monolayer cultures 
in high-glucose DMEM supplemented with 20% fetal bovine serum, 37.5 µg/ mL of ascorbic 
acid, 300 µg of L-glutamine/mL 100 U of sodium penicillin/mL, and 100 µg of streptomycin 
sulfate/mL. The rapidly adherent, fibroblast-like cells were excluded by transferring the 
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unattached cells to fresh culture flasks after 24 hrs. The transferred cells were grown to 
confluence, and then passaged twice. TDPCs from the confluent, second passage cultures were 
used for intra-lesional injections. The multipotentiality of these expanded cells was tested using 
standard adipogenic, osteogenic and chondrogenic assays, as previously described [8,9]. 
 
Cell Labeling: For the TDPC distribution and survival assessment, 5 µL of 1,1’dioctadecyl-
3,3,3’, 3’-tetramethylindocarbocyanine percholate (DiI); (Molecular Probes, Eugene, OR) was 
added to each 1 x 106 cell aliquot in 1 mL of HBSS and incubated for 30 minutes at 37 0C.17 The 
cells were then washed four times with HBSS to remove excess dye prior to injection. Post-
labeling cell viability was confirmed via trypan blue (Sigma-Aldrich, St. Louis, MO) exclusion 
test.  
 
TDPC Injections: Four weeks following collagenase injections, one randomly selected forelimb 
of each horse was injected with 5 x 106 TDPCs in 0.15 mL of sterile phosphate buffered saline 
(TDPC group) at the two sites (1 x 107 cells in total) corresponding to collagenase injection, 
under ultrasonographic guidance [13,15]. The contralateral forelimb SDF tendon was injected 
with an equal volume of saline (saline group) in a similar manner. For the following month, the 
horses were hand-walked for 5 minutes once a day. During the fourth month, all horses were 
hand-walked for 10 minutes once a day.  
        
The lesions in the hind SDF tendons were injected with 5 x 106 DiI-labeled TDPCs (as described 
above) at 1, 2, 4 or 6 weeks (n=2 at each time point) prior to termination of the study.  
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Tendon Harvesting and Sample Allocation: All horses were euthanized with pentobarbital 
overdose 12 weeks after the forelimb TDPC and saline injections. The SDF tendons were 
collected sterilely immediately after euthanasia. Both forelimb and the normal hindlimb SDF 
tendons were axially divided. One half of each tendon was frozen at -800 C for biomechanical 
testing. The repair tissue in the remaining hemi-tendon was sectioned transversely into 4 
specimens, all from within the grossly pathological tissue, and allocated to endpoint analyses as 
depicted in Figure 5.2. The specimens were snap-frozen in liquid nitrogen for RNA isolation, 
biochemical assays, fixed in OCT compound or 4% paraformaldehyde for histologic processing. 
Macroscopically injured regions of the hind SDF tendons (injected with the DiI-labeled TDPCs) 
were sectioned transversely and fixed in OCT compound for histologic processing.   
 
RNA Isolation and Quantitative RT-PCR: RNA was isolated by a previously described 
protocol [12]. Briefly, tendons were pulverized under liquid nitrogen, homogenized in 
guanidinium isothiacyanate lysis buffer, extracted in phenol-chloroform and precipitated in 
isopropanol. The resultant pellet was purified using RNeasy column-based protocol that included 
an on-column DNase digest. One µg of RNA from each sample was reverse-transcribed 
(Superscript II, Invitrogen, Carlsbad, CA) using oligo(dT) primers. Gene-specific primers for 
collagen types I and III, cartilage oligomeric matrix protein (COMP) and tenomodulin were 
designed from published sequences in Genbank, and using ClustalW multiple sequence 
alignment (available at www.ebi.ac.uk). Primer specificity was confirmed by cloning and 
sequencing the amplicons during optimization experiments, as previously described (Table 5.1) 
[16]. PCR amplifications were catalyzed by Taq DNA polymerase (BioRad iCycler, Bio-Rad 
Laboratories, Hercules, CA) in the presence of Sybr green. Relative gene expression was 
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quantified using the 2-∆∆CT method, normalized to expression of the reference gene, elongation 
factor-1α (EF1α) [18]. 
 
Biochemical Assays: Ten mg of tendon tissue was digested overnight in 0.1% papain (Sigma, St. 
Louis, MO) at 65° C.  Sulfated glycosaminoglycan (sGAG) content was measured by the 
dimethylmethylene blue (DMMB) dye-binding assay, as previously described, using ovine 
chondroitin sulfate to generate a standard curve [19]. DNA content was determined by 
fluorometric measurement of Hoechst 33258 (Sigma, St. Louis, MO) dye incorporation [19].  
       
Total soluble collagen content was determined using a commercially available kit (Biocolor, 
Carrickfergus, County Antrim, UK) following overnight digestion of 10 mg of tendon samples in 
1.3mg/mL pepsin [14]. 
 
Biomechanical Testing: The tendon specimens were thawed to room temperature prior to 
testing. Each tendon was sectioned axially in the longitudinal plane to generate two samples 
(each comprising one quarter of the tendon), to ensure secure anchorage and assess 
biomechanical variability. Mean cross-sectional area of each sample was calculated by averaging 
three separate measurements taken at the injured region with vernier calipers. The quarter-tendon 
specimens were tested individually and the data were averaged to provide single values for each 
sample. The tendon ends were secured in a hydraulic testing device (Instron 8511, Norwood, 
MA) using custom-designed, serrated clamps, with the lesion centered between the clamps.21 
The SDF tendon specimens used for biomechanical testing ranged from 35-40 cm. Between 6 
and 8 cm at each end was engaged in the serrated clamps, leaving 10-15 cm gauge length. The 
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gross tendon lesions were 8-10 cm in length, comprising 60-80% of the tissue between the 
clamps. All tendons were pre-conditioned at 1% strain for 10 cycles prior to tensile testing. The 
tendons were loaded to failure in tension at a strain rate of 2.5%/second. Load-displacement 
values were acquired at 10 Hz. Displacement was measured as change in grip-to-grip distance. 
These values were normalized to the mean cross-sectional area of the samples to obtain stress-
strain data. Yield stress and maximum stress (N/cm2 = MPa) were calculated by dividing the 
yield load (N) and maximum load (N) by the mean cross-sectional area (cm2). The slopes of the 
linear portion of the stress-strain curves were used to calculate elastic modulus.  
 
Histology: The paraformaldehyde-fixed samples were paraffin-embedded using standard 
protocols. Sections were cut to 6-µm and stained with Picro-Sirius Red (Sigma, St. Louis, MO) 
or Toluidine Blue (Sigma, St. Louis, MO). The OCT-preserved samples were sectioned at -200C 
to 10-µm using a cryostat (Leica CM3050S, Ramsey, MN) for SHG, DiI and DAPI imaging.   
 
Fluorescence microscopy: The cryo-sections from the hind SDF tendons injected with DiI-
labeled TDPCs were mounted with diamidino phenyl indole (DAPI; Vector Laboratories, 
Burlingame, CA) for nuclear fluorescence. The sections were imaged with a fluorescence 
microscope (Zeiss Axiovert 200M, Peabody, MA) with the apotome-structured illumination 
optical sectioning system. Excitation wavelengths of 358 nm and 459 nm were used for DAPI 
and DiI respectively.  
 
Second Harmonic Generation (SHG) microscopy and Fourier Transformation (FT): SHG 
images were obtained from longitudinal cryosections via confocal microscopy as previously 
 
91 
described [22]. Five cryosections were made from the mid-sections of each tendon specimen 
(normal, saline and TDPC) from each horse. SHG images were obtained from 5 random fields in 
each section. Collectively, 200 data points were used to compare SHG-derived indices of 
collagen alignment in the three groups.  A modified confocal system (Zeiss LSM 710, Peabody, 
MA) equipped with a tunable Ti:Sapphire laser source that produced 70 fs pulses (80MHz 
repetition rate) was used to image the samples. An excitation wavelength of 780 nm was used to 
generate SHG emission from collagen fibers at all orientations. The beam was reflected by a 
short-pass 760 nm dichroic mirror and focused onto the sample using a 40X water-immersion 
objective. The backward SHG emissions were collected by the same objective. The images were 
Fourier-Transformed using imageJ software (http://rsweb.nih.gov/ij/). A gray-scale image 
representative of spatial distribution of collagen fiber orientation was obtained, as previously 
described [22]. A single value (in degrees) for the mean orientation of the collagen fibers, was 
calculated from each group, with ‘900’ representing consistent longitudinal alignment. 
 
Statistical Analyses: All data were normally distributed. Descriptive statistics were reported as 
mean and standard error of the mean (SE). The treated tendons were compared to each other as 
well as the control tendon using repeated measures one-way analysis of variance (ANOVA) and, 
where indicated, Holm-Sidak post hoc comparisons. For all analyses, SigmaStat 4 software 
(Systat Software, San Jose, CA) was used. The p values reported in our results represent 
differences obtained from post-hoc comparisons. A p value < 0.05 was considered statistically 
significant. 
 
 
 
92 
Results: 
Cell Survival and Distribution (Figure 5.3): DiI fluorescence of the labeled TDPCs was 
visualized along with nuclear DAPI fluorescence in the hindlimb SDF tendon cryosections. The 
TDPCs were present in large clusters at the injection sites, 1 week after administration. At 2 
weeks, there were substantially fewer TDPCs remaining at the injection sites, and they appeared 
to be linearly distributed along with the native tenocytes. Very few labeled TDPCs were present 
at the 4-week time point, and no labeled cells were detectable by 6 weeks. 
 
Gene Expression: Collagen type I, COMP and tenomodulin mRNA levels were significantly 
increased in both TDPC and saline groups compared to the normal tendon (Table 5.2). There 
were no significant differences between the experimental groups. Collagen type III mRNA levels 
were also substantially higher in the TDPC (approximately 12-fold) and saline (approximately 
20-fold) groups but, because of considerable inter-animal variability, these differences did not 
reach statistical significance (Table 5.2). 
 
Biochemical Analyses: DNA content, reflecting cellularity, was significantly higher 
(approximately 20%) in both the TDPC and saline groups, compared to normal controls. 
However, the total collagen and sGAG contents of the experimental groups were not different 
from those of normal tendon (Table 5.3).  
 
Biomechanical Properties: The results of the quarter-tendon tests from each specimen were 
highly similar. All tendons failed within the gauge length at the healthy-damaged tissue 
interface. Grossly, failure occurred through longitudinal extension of the interfaces between 
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collagen bundles until complete separation occurred (Supplementary video), as opposed to an 
abrupt transversely oriented failure. The mean cross sectional area of the normal tendons (0.8 + 
0.01 cm2) was significantly less than the areas of the TDPC (2.29 + 0.2 cm2; p = 0.02) and saline 
(2.57 + 0.28 cm2; p = 0.024) groups. Yield stresses of the TDPC-injected and normal tendon 
were statistically similar (p = 0.3) and significantly higher than the saline group (p = 0.005; 
Figure 5.4). Similarly, the maximum stresses of the TDPC-injected and normal tendon were 
statistically similar (p = 0.07) and significantly higher than the saline group (p < 0.001; Figure 
5.4). The elastic modulus of TDPC and saline groups were statistically similar (p = 0.2) and both 
were significantly lower than normal tendons (p = 0.002, and p < 0.001, respectively; Figure 
5.4). Similarly, the stiffness of TDPC (10,200 + 546 N/cm) and saline (9,600 + 432 N/cm) 
groups were significantly lower than normal tendons (14,032 + 945 N/cm; p < 0.001 in both 
comparisons) and not significantly different (p = 0.2) from each other.  
 
Histology: As shown in Picro Sirius Red-stained sections, the collagen microarchitecture of the 
TDPC tendons was more longitudinally aligned and the crimp pattern more organized than the 
saline group (Figure 5.5). Sulfated GAG distribution in the Toluidine Blue-stained sections of 
the TDPC group tendons was comparable to normal tendons, whereas metachromasia was more 
apparent in the saline-injected tendons (Figure 5.6). Consistent with these observations, Fourier 
Transform analyses from the SHG images (Figure 5.7) demonstrated that collagen fibers were 
significantly (p = 0.03) more aligned in TDPC sections (mean = 105.67 + 8.3 degrees) than in 
saline sections (mean = 114.7 + 16.2 degrees) and similar (p = 0.1) to values from normal 
tendons (mean = 98.4 + 6.2 degrees).  
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Discussion: 
This study was carried out to determine the effects of equine TDPCs on tendon healing in a 
collagenase model of tendinitis. We hypothesized that autogenous TDPCs will improve tendon 
healing, as assessed by transcriptional, biochemical, biomechanical, and histologic outcomes. 
Intralesional TDPC injections did improve the tensile strength of the repair tissue, reflected by 
increased yield and maximum stresses, and also significantly improved collagen fiber alignment 
in the repair tissue, as measured by Fourier transform SHG (FT-SHG). In contrast, the 
biochemical and transcriptional outcomes were not significantly influenced by TDPC injections. 
These outcomes are somewhat limited because relatively small samples of the affected tissues 
were used (Figure 5.2) and these may not represent the overall status of the healing tissues, 
given the spatial variability in the pathology generated by collagenase injections and subsequent 
reparative responses; an intrinsic limitation of this large animal model. 
           
Normal hind limb SDF tendons were used as ‘within animal’ controls in this study, in addition to 
the matched contralateral, saline-injected tendons. Accepting that loading and extension are 
higher in fore limb SDF tendons than in hind limbs [23], we consider that hind limb tendon 
provided satisfactory matched reference values to compare healing in fore limb SDF tendons. 
The biomechanical data were normalized to tendon cross-sectional area, to exclude variability 
derived from morphometric differences.  
          
The effects of autogenous TDPCs in this study are similar to the outcomes of studies 
investigating other cell-based therapies for experimental tendinitis, such as BM-MSCs 
[14,24,25], adipose-derived nucleated cells [14] and fetal-derived embryonic stem cells [15]. 
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Although collagen gene expression was increased in TDPC (p = 0.02) and saline (p = 0.03) 
groups compared to normal tendon, there was no significant difference in the collagen contents. 
This ‘disconnect’ between transcriptional and translational outcomes has been reported in other 
cell-based tendinitis studies [14,15] and is likely due to gene up-regulation without subsequent 
translation and/or rapid turnover of newly synthesized matrix proteins. Significant improvements 
in collagen micro-architecture were reported in all these studies, using semi-quantitative 
histologic analyses. Despite the improved matrix organization, Chong et al. [26] and Schnabel et 
al. [14] found only marginal improvements in biomechanical strength.  
           
In the current study, the tensile and material properties of the entire tendon (both healthy and 
‘repair’ regions) were measured, similarly to other studies [14,26]. The grossly pathological 
regions in the saline and TDPC groups comprised 60-80% of the gauge length, while normal 
tendon was engaged in the serrated clamps at each end. Accepting that mechanical testing of the 
‘repair’ region in isolation would provide more specific biomechanical characterization of the 
healing tissue, the entire tendon was tested in this study to determine the overall/global 
biomechanical properties of the weight-bearing structure. The yield stress (point of initial 
collagen fiber disruption) and maximum stress (point of complete tendon disruption) of the 
TDPC group were not significantly different from those of normal tendons, whereas these 
parameters were significantly lower in the saline group. In contrast, the elastic modulus of the 
TDPC group was significantly less than that of normal tendons (about 50% of normal values), 
although higher than the saline controls. Elastic modulus is a sensitive indicator of energy-
storing capacity and elastic recovery after loading. Incomplete restoration of elastic modulus in 
damaged tendons reflects the high recurrence rates of these injuries. Given the prolonged time 
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frame of recovery in clinical tendonitis cases (8-12 months), it is possible that elastic modulus 
continues to improve over time frames longer than the current study (12 weeks) [27]. Further 
long-term studies will be necessary to determine the long-term effect of TDPCs on the 
biomechanical properties of healing tendon and functional recovery in clinical cases.   
            
Custom-made plastic, serrated jaw clamps adapted from a previous study [21] were used for 
rigid gripping of tendons in this study. Tensile failure tests with equine tendons can be 
confounded by the clamp design, the interface properties between the fixed points and the tendon 
tissue, and amount of normal tendon present between the grips [14]. The set-up used in this study 
was uncomplicated, did not require freezing or PMMA anchoring of the tendon ends, and 
supported tensile testing to failure at high loads. All tendons failed at the healthy-injured tendon 
interface, rather than the clamp-tendon interface. Equine tendons absorb tensile load through 
fascicle extension and sliding between collagen bundles rather than fiber extension and rupture 
alone, prior to failure [28,29]. This ‘sliding’ mechanism of failure was noted during testing of the 
tendon samples in the current study. This indicates that restoration of tertiary hierarchical 
structure is critical to functional tendon repair, in addition to recovery of a characteristic collagen 
fiber crimp pattern. 
            
The clinical use of autologous TDPCs for treating tendon injuries is dependent on identifying a 
suitable donor site. In this study, TDPCs were isolated from a small portion of the LDE tendon 
and was collected with little difficulty at the time of the collagenase injections. Tenectomy of the 
LDE is used to treat refractory stringhalt in horses, with minimal post-surgical morbidity. 
Nevertheless, a tenectomy procedure is more invasive than bone marrow aspiration or adipose 
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tissue collection. Additional outcome analyses will be required to determine whether any clinical 
benefits derived from TDPCs justify the more complex collection procedure. Tenocytes from 
extensor tendon are less proliferative than digital flexor tenocytes and have a lower matrix-
synthesis rate [30]. It is not clear whether these differences in primary tenocyte populations are 
retained through the extensive in vitro selection and expansion protocol used to generate TDPCs, 
but progenitors derived from digital flexor tendons may prove to be more clinically effective 
than LDE-derived cells, provided an innocuous flexor tendon donor site can be identified. 
TDPCs have a relatively high in vitro proliferation capacity, so only a small amount of 
autogenous tendon is required to generate clinically useful cell numbers [16,31]. In human 
patients, healthy tendon autografts are routinely obtained from patellar tendon and palmaris 
longus tendon, for cruciate [32,33] and ulnar collateral ligament [34] reconstruction respectively. 
These could also be used as sources for autogenous TDPC isolation. Pathologic tendon tissues 
excised during surgical repair of Achilles tendons [35] and rotator cuff injuries [36] could also be 
used to isolate autogenous TDPCs; however, the characteristics of TDPCs from diseased tissue 
would need to be evaluated before this option can be considered feasible. Alternatively, 
allogeneic TDPCs avoid potential donor-site complications and extended culture intervals 
required for autogenous cells. Allogeneic primary TDPCs [37], adipose-derived nucleated cells 
[38], BM-MSCs [39] and fetal-derived embryonic stem cells [15] implanted within experimental 
tendon lesions had similar survival and distribution patterns as reported in this study. 
Histological improvements in collagen architecture were seen without adverse immune reactions. 
These findings support further studies in this regard.  
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FT-SHG imaging of cryosectioned tendon samples provided an objective and quantitative 
method to assess collagen fiber alignment in healing tendons and corroborate visual assessments 
of collagen alignment in the Picro-Sirius Red-stained sections (Figure 5.5). Over the last decade, 
SHG microscopy has been adapted to evaluate spatial distributions of fibrillar proteins, 
particularly collagen, utilizing non-centrosymmetric property of collagen molecules, whereby 
light at half the wavelength of incident light is emitted following interaction with collagen 
[40,41]. High-resolution images are produced without the need for special staining and 
associated chemical and/or thermal processing that might disrupt the integrity of the tissue 
samples. In this respect, FT-SHG constitutes a valuable tool for ongoing and future tendon repair 
studies, since the modality provides high-resolution, spatially distinct and quantitative indices of 
collagen fiber orientation throughout the repair site.  
           
Improved collagen microarchitecture is a consistent finding across studies evaluating cell-based 
therapies. Accepting this, the mechanisms by which cell-based therapies improve the matrix 
organization of healing tendons are poorly understood. In vivo cell tracking studies have reported 
that very few MSCs remain around the injection site beyond a few weeks [42,43], indicating that 
their therapeutic impact likely occurs during their transient presence at the repair site and does 
not involve major direct contributions to new matrix synthesis [14-16, 36,39]. Local cytokine 
modulation and trophic factor synthesis have been proposed as likely mechanisms by which 
MSCs influence tissue regeneration [44-46]. Identifying soluble factors that mediate ‘stem cells’ 
therapeutic effects could simplify biologic therapy considerably, if cell-based therapies do 
influence repair through secreted proteins. Although the quantities and orientation of large 
fibrillary collagen molecules (types I and III) are routinely analyzed in tendon repair studies, it is 
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also possible that MSCs influence the intrinsic healing response by modulating non-fibrillar 
collagens and other small matrix molecules that are critical to formation of fibrillar collagen 
higher order structures [47,48]. In light of the findings of this study, further investigations on the 
clinical use mechanisms of action of TDPCs for the treatment of tendon injuries are warranted. 
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Tables and Figures: 
 
 
 
 
Table 5.1: Primers used for real-time PCR amplification of genes of equine bone marrow– and 
tendon-derived cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.2.  Quantitative PCR analysis of mRNA levels. Transcript abundance in the TDPC and 
saline groups was normalized to expression in the normal tendon within each horse, which was 
accorded a value of ‘1.00’. Fold changes are represented as mean + SE (n = 8). 
 
 p values refer to the outcomes of Holm-Sidak post hoc comparisons to normal tendon values. * Indicates a 
significant difference.  
 
Gene  Sequence Amplicon 
(bp) 
Col I  S 
A 
5’ GAA AAC ATC CCA GCC AAG AA 
5’ GAT TGC CAG TCT CCT CAT CC 
231 
Col III  S 
A 
5’ AGG GGA CCT GGT TAC TGC TT 
5’ TCT CTG GGT TGG GAC AGT CT 
215 
COMP  S 
A 
5’ TCA TGT GGA AGC AGA TGG AG 
5’ TAG GAA CCA GCG GTA GGA TG 
223 
Tenomodulin S 
A 
5’ CCC GTG ACC AGA ACT GAA AT 
5’ GTT GCA AGG CAT GAT GAC AC 
232 
EF1-alpha S 
A 
5’ CCC GGA CAC AGA GAC TTC AT 
5’ AGC ATG TTG TCA CCA TTC CA 
328 
Transcript Saline TDPC 
Collagen type I  9.76 + 2.90* 
p = 0.03 
7.48 + 1.50* 
p = 0.02 
Collagen type III  20.79 + 8.76 
p = 0.06 
12.81 + 3.45  
p = 0.07 
COMP  3.17 + 0.74* 
p = 0.03 
3.13 + 0.60* 
p = 0.02 
Tenomodulin  18.23 + 5.74* 
p < 0.001 
23.32 + 7.05* 
p = 0.02 
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Table 5.3.  Biochemical analyses of DNA, sulfated glycosaminoglycans and collagen content of 
treated and normal tendons. Data are represented as mean + SE (n = 8).  
 
p values refer to the outcomes of Holm-Sidak post hoc comparisons to normal tendon values. * indicates a 
significant difference.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Molecule Normal Saline TDPC 
DNA content 
µg/100 mg 
21.80 + 3.84 26.94 + 3.13* 
p = 0.03 
25.64 + 3.24* 
p = 0.02 
Total collagen 
content µg/100 mg 
22.57 + 5.54 23.98 + 2.92 
p = 0.70 
23.71 + 4.13 
p = 0.56 
Total sGAG 
content µg/100 mg 
44.74 + 4.23 43.44 + 3.02 
p = 0.43 
44.96 + 3.05 
p = 0.21 
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Figure 5.1: Schematic representation of the study design (over 16 weeks). 
C - collagenase injection; L - LDE tenectomy; T - TDPC injection; D - DiI-labeled TDPC 
injection.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: Schematic representation of sample allocation from normal, TDPC- and saline-
treated SDF tendons. The irregular shaded region represents collagenase-injured tissue.   
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Figure 5.3: Fluorescence microscopic images of longitudinal cryosections of SDF tendons (A) 
1week, (B) 2 weeks, (C) 4 weeks, and (D) 6 weeks after intra-lesional injections of DiI-labeled 
TDPCs. Bar = 100 microns. 
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Figure 5.4: (A) Mean tensile yield and maximum stresses (Mpa) of normal, saline and TDPC 
tendons. Bars represent mean + SE (n = 8). * Indicates a significant difference from normal 
tendons. (B) Mean elastic modulus (Mpa) of normal, saline and TDPC tendons. Bars represent 
mean + SE (n = 8). * Indicates a significant difference from normal tendons.  
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Figure 5.5: Picro-Sirius Red-stained longitudinal sections of (A, D) normal, (B,E) saline, and 
(C, F) TDPC tendons under polarized light. Panels A, B and C are high magnification images, 
while panels D, E and F are low magnification mages. In all panels, the scale bar = 100 microns. 
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Figure 5.6: Toluidine Blue-stained longitudinal sections of (A, D) normal, (B, E) saline, and (C, 
F) TDPC tendons under polarized light under bright-field microscopy. Panels A, B and C are 
high magnification images, while panels D, E and F are low magnification mages. In all panels, 
the scale bar = 100 microns.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B C
 
E
 
F
 
D
 
 
107 
 
 
 
 
 
 
Figure 5.7: SHG images of longitudinal cryosections of (A) normal, (B) saline, and (C) TDPC 
tendons obtained by confocal microscopy. The corresponding Fourier distributions of collagen 
orientation are shown in panels (D), (E) and (F). In all panels, the scale bar = 100 microns.  
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CHAPTER 6: CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
The first set of results presented in this dissertation (chapter 3) addressed the isolation and in 
vitro characterization of equine tendon-derived progenitor cells. Differential adherence 
preplating did not enrich equine TDPC isolation during in vitro culture and monolayer 
expansion. Preplating did not alter the in vitro growth/proliferation characteristics of TDPCs. 
The immunophenotype and trilineage differentiation potential of the three TDPC fractions 
assessed in this study was similar. Overall, TDPCs had robust osteogenic capacity but minimal 
adipogenic and chondrogenic capacity. These results indicate that whole digest tendon-derived 
cell stocks are adequate for enrichment of progenitor cells via monolayer expansion.  
 
Understanding the basics of TDPC biology is critical for their successful application in tendon 
repair/regeneration. To date, markers specific to TDPCs and tenocytes in general are poorly 
defined, and a reliable in vitro tenogenic differentiation assay is still lacking, although research 
efforts in this area are ongoing. TDPCs are heterogeneous cells and therefore developing a single 
marker that can definitively identify TDPCs is likely not feasible. Studies focusing on identifying 
a panel of co-expressed markers to define TDPCs are more realistic. Self-evidently, determining 
whether any given immunophenotypic tendon-derived sub-population holds any therapeutic 
advantage will also need to be addressed in rigorous in vivo models.   
 
The experiments addressing the in vitro tendon matrix synthesis revealed significantly higher 
capacity in TDPCs compared to donor-matched BM-MSCs (chapter 4). Based on these 
promising results, the in vivo healing capacity of equine TDPCs was evaluated in a collagenase 
model of superficial digital flexor tendinitis. Intralesional injections of autogenous TDPCs 
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improved the biomechanical and histological properties of healing tendon tissue (chapter 5).  
Tendon healing in experimental models has been substantially improved with cell-based and 
other biologic approaches, although these therapies do not completely restore the tissue 
microarchitecture. With the data from recent cell-tracking studies, it is well established that 
exogenous stem cells are cleared from the injection site within a few weeks and do not directly 
contribute to the pool of tenocytes and/or progenitor cell participating in tendon 
repair/regeneration. Future studies focusing on cytokines and/or trophic factors secreted by 
TDPCs that mediate their therapeutic effects could simplify therapy considerably. Optimizing 
stem cell delivery by combining cells with teno-inductive scaffolds may retain cells at the 
implantation site for longer periods of time, with correspondingly longer therapeutic actions. 
          
Restoring the biomechanical function of repair tissue should be the ultimate goal of any 
regenerative therapy for treating tendon injuries. Tendons respond to tensile loads via elongation 
and sliding mechanism between each element of the hierarchical structure. As the gross and 
microscopic structure of tendons is disrupted in tendon injury, the ideal regenerative therapy 
must restore the hierarchical structure of tendons and the sliding mechanisms of the tendon 
components, in addition to improving collagen alignment to regain full biomechanical function. 
Currently, collagen fiber pattern along the long axis of the tendon is the major outcome 
parameter used to assess tissue morphology but this does not address restoration of tertiary 
structure. Developing non-invasive and histological techniques that comprehensively assess 
tendon histology at multiple levels of matrix organization will be vital to comprehensively 
evaluate new therapies.  
 
114 
Finally, clinical use of TDPCs for treating tendon injuries is dependent on identifying a suitable 
tissue source, with minimal donor site morbidity. In general, a tenectomy procedure for isolating 
autologous TDPCs is more invasive than bone marrow aspiration. In our in vivo study, 
autologous equine TDPCs were derived from the lateral digital extensor tendon with minimal 
post-operative morbidity. In human patients, healthy tendon autografts are routinely obtained 
from patellar and palmaris longus tendons, for cruciate and ulnar collateral ligament 
reconstruction surgeries, respectively. These sites could also be used for autogenous TDPC 
isolation. Further work is needed in this regard. Tendon tissues excised during reparative 
surgeries of Achilles tendon and rotator cuff injuries could also be used to isolate autogenous 
TDPCs; however, given the altered characteristics of TDPCs from pathological tissues, further 
research on these TDPCs is required before this possibility can be considered feasible. 
Allogeneic TDPCs can also be considered, as they avoid donor-site complications and culture 
delays that are required to generate clinically relevant autologous cell numbers. Although several 
in vivo experimental studies demonstrate the therapeutic benefits of allogeneic TDPCs, major 
regulatory and immunogenic concerns exists to prevent translating this option to human tendon 
injuries.  
 
 
 
 
